<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="82b124e9-01d4-4e8c-b9cc-0dec0dc282a5"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use DAPTOMYCIN FOR INJECTION safely and effectively. See full prescribing information for DAPTOMYCIN FOR INJECTION. <br/>
      <br/>DAPTOMYCIN for injection, for intravenous use  <br/>Initial U.S. Approval: 2003</title>
   <effectiveTime value="20250227"/>
   <setId root="1957b6ce-7382-4a7b-bf02-3595948d09c6"/>
   <versionNumber value="5"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="141588017" root="1.3.6.1.4.1.519.1"/>
            <name>Hospira, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="758967652" root="1.3.6.1.4.1.519.1"/>
                        <name>Hospira Australia Pty Ltd</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0409-0120" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0409-0122" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0409-0120" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0409-0122" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0409-0120" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0409-0122" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0409-0120" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0409-0122" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="827731089" root="1.3.6.1.4.1.519.1"/>
                        <name>Hospira, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0409-0122" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0409-0120" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="9a0a54a2-5fe3-47c9-8f6e-acabf2df90c2"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20220818"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0409-0122" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Daptomycin</name>
                        <formCode code="C42957" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>DAPTOMYCIN</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="500"/>
                              <denominator unit="mL" value="10"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="NWQ5N31VKK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DAPTOMYCIN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="NWQ5N31VKK" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DAPTOMYCIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XF417D3PSL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS CITRIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="10"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0409-0122-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20210802"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA210282" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20210802"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0409-0120" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Daptomycin</name>
                        <formCode code="C42957" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>DAPTOMYCIN</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="350"/>
                              <denominator unit="mL" value="7"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="NWQ5N31VKK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DAPTOMYCIN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="NWQ5N31VKK" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DAPTOMYCIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XF417D3PSL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS CITRIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="7"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0409-0120-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20210802"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA210282" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20210802"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="5bbefd0b-e4ae-4226-b139-ead2c86f4c11"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20220818"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Daptomycin for Injection is a lipopeptide antibacterial indicated for the treatment of:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Complicated skin and skin structure infections (cSSSI) in adult patients (<linkHtml href="#S1.1">1.1</linkHtml>) and,</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="italics">Staphylococcus aureus</content> bloodstream infections (bacteremia), in adult patients including those with right-sided infective endocarditis, (<linkHtml href="#S1.2">1.2</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use:</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>This Daptomycin for Injection product is not approved for use in pediatric patients. (<linkHtml href="#S1.3">1.3</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Daptomycin for Injection is not indicated for the treatment of pneumonia. (<linkHtml href="#S1.3">1.3</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Daptomycin for Injection is not indicated for the treatment of left-sided infective endocarditis due to <content styleCode="italics">S. aureus</content>. (<linkHtml href="#S1.3">1.3</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Daptomycin for Injection is not recommended in pediatric patients younger than one year of age due to the risk of potential effects on muscular, neuromuscular, and/or nervous systems (either peripheral and/or central) observed in neonatal dogs. (<linkHtml href="#S1.3">1.3</linkHtml>)</item>
                        </list>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of Daptomycin for Injection and other antibacterial drugs, Daptomycin for Injection should be used to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (<linkHtml href="#S1.4">1.4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S1.1">
                     <id root="8a35bd22-e5a5-473d-937f-bcac573a73de"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1	Complicated Skin and Skin Structure Infections (cSSSI)</title>
                     <text>
                        <paragraph>Daptomycin for Injection is indicated for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive bacteria: <content styleCode="italics">Staphylococcus aureus</content> (including methicillin-resistant isolates), <content styleCode="italics">Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis,</content> and <content styleCode="italics">Enterococcus faecalis</content> (vancomycin-susceptible isolates only).</paragraph>
                     </text>
                     <effectiveTime value="20220818"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.2">
                     <id root="b4271448-854d-48e7-940c-a5ca642504bc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2	<content styleCode="italics">Staphylococcus aureus</content> Bloodstream Infections (Bacteremia) in Adult Patients, Including Those with Right-Sided Infective Endocarditis, Caused by Methicillin-Susceptible and Methicillin-Resistant Isolates</title>
                     <text>
                        <paragraph>Daptomycin for Injection is indicated for the treatment of adult patients with <content styleCode="italics">Staphylococcus aureus</content> bloodstream infections (bacteremia), including adult patients with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates.</paragraph>
                     </text>
                     <effectiveTime value="20220818"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.3">
                     <id root="e8942b32-3664-48ed-afa7-ed0db009bd95"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.3	Limitations of Use</title>
                     <text>
                        <paragraph>This Daptomycin for Injection product is not approved for use in pediatric patients <content styleCode="italics">[see <linkHtml href="#S8.4">Use in Specific Populations (8.4)</linkHtml>]</content>.</paragraph>
                        <paragraph>Daptomycin for Injection is not indicated for the treatment of pneumonia.</paragraph>
                        <paragraph>Daptomycin for Injection is not indicated for the treatment of left-sided infective endocarditis due to <content styleCode="italics">S. aureus</content>. The clinical trial of daptomycin for injection in adult patients with <content styleCode="italics">S. aureus</content> bloodstream infections included limited data from patients with left-sided infective endocarditis; outcomes in these patients were poor <content styleCode="italics">[see <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>]</content>. Daptomycin for Injection has not been studied in patients with prosthetic valve endocarditis.</paragraph>
                        <paragraph>Daptomycin for Injection is not recommended in pediatric patients younger than 1 year of age due to the risk of potential effects on muscular, neuromuscular, and/or nervous systems (either peripheral and/or central) observed in neonatal dogs <content styleCode="italics">[see <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml> and <linkHtml href="#S13.2">Nonclinical Toxicology (13.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20220818"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.4">
                     <id root="7ecc6055-e27c-411b-9460-e7cbea0e5b5f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.4	Usage</title>
                     <text>
                        <paragraph>Appropriate specimens for microbiological examination should be obtained in order to isolate and identify the causative pathogens and to determine their susceptibility to daptomycin.</paragraph>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of Daptomycin for Injection and other antibacterial drugs, Daptomycin for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.</paragraph>
                        <paragraph>When culture and susceptibility information is available, it should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Empiric therapy may be initiated while awaiting test results.</paragraph>
                     </text>
                     <effectiveTime value="20220818"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="d6df618f-6dba-44ed-a8a9-7494db589acc"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Adult Patients</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Administer to <content styleCode="bold">adult patients</content> intravenously in 0.9% sodium chloride, either by injection over a 2-minute period or by infusion over a 30-minute period. (<linkHtml href="#S2.1">2.1</linkHtml>, <linkHtml href="#S2.5">2.5</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Recommended dosage regimen for adult patients (<linkHtml href="#S2.2">2.2</linkHtml>, <linkHtml href="#S2.3">2.3</linkHtml>, <linkHtml href="#S2.4">2.4</linkHtml>):</item>
                        </list>
                        <table width="100%">
                           <col width="33%"/>
                           <col width="33%"/>
                           <col width="34%"/>
                           <thead>
                              <tr>
                                 <th align="left" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <content styleCode="bold">Creatinine Clearance (CrCl)</content>
                                 </th>
                                 <th align="center" colspan="2" styleCode="Rrule Botrule Toprule " valign="top">
                                    <content styleCode="bold">Dosage Regimen</content>
                                 </th>
                              </tr>
                              <tr>
                                 <th align="center" styleCode="Rrule Botrule " valign="top">
                                    <content styleCode="bold">
                                       <content styleCode="underline">cSSSI</content>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">For 7 to 14 days</content>
                                 </th>
                                 <th align="center" styleCode="Rrule Botrule " valign="top">
                                    <content styleCode="bold">
                                       <content styleCode="underline">
                                          <content styleCode="italics">S. aureus</content> Bacteremia</content>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">For 2 to 6 weeks</content>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>≥30 mL/min</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                    <paragraph>4 mg/kg once every 24 hours</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                    <paragraph>6 mg/kg once every 24 hours</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>&lt;30 mL/min, including hemodialysis and CAPD</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Toprule " valign="top">
                                    <paragraph>4 mg/kg once every 48 hours<footnote ID="_Reffoot">Administered following hemodialysis on hemodialysis days.</footnote>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>6 mg/kg once every 48 hours<footnoteRef IDREF="_Reffoot"/>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>There are other formulations of daptomycin that have differences concerning storage and reconstitution. Carefully follow the reconstitution and storage procedures described in this labeling. (<linkHtml href="#S2.5">2.5</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Do not use in conjunction with ReadyMED<sup>®</sup> elastomeric infusion pumps in adult patients. (<linkHtml href="#S2.5">2.5</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="01d1acfa-089e-4f3d-8e2f-609a47ddc1d9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1	Important Administration Duration Instructions</title>
                     <effectiveTime value="20220818"/>
                     <component>
                        <section ID="ID_f74e5094-4d50-4c8c-9622-7c8b3b4ff7a6">
                           <id root="b1891520-9bc2-4778-977a-89c4a7c827dd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adults</content>
                              </paragraph>
                              <paragraph>Administer the appropriate volume of the reconstituted Daptomycin for Injection (concentration of 50 mg/mL) <content styleCode="bold">to adult patients</content> intravenously either by injection over a two (2) minute period or by intravenous infusion over a thirty (30) minute period <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2</linkHtml>, <linkHtml href="#S2.3">2.3</linkHtml>, <linkHtml href="#S2.5">2.5)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20220818"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="36c26216-2ff8-4afe-9102-a9ef31c31136"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2	Dosage in Adults for cSSSI</title>
                     <text>
                        <paragraph>Administer Daptomycin for Injection 4 mg/kg to adult patients intravenously in 0.9% sodium chloride injection once every 24 hours for 7 to 14 days.</paragraph>
                     </text>
                     <effectiveTime value="20220818"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="64b1bceb-23ff-4e52-9f3a-dcb127105e3c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3	Dosage in Adult Patients with <content styleCode="italics">Staphylococcus aureus</content> Bloodstream Infections (Bacteremia), Including Those with Right-Sided Infective Endocarditis, Caused by Methicillin-Susceptible and Methicillin-Resistant Isolates</title>
                     <text>
                        <paragraph>Administer Daptomycin for Injection 6 mg/kg to adult patients intravenously in 0.9% sodium chloride injection once every 24 hours for 2 to 6 weeks. There are limited safety data for the use of daptomycin for injection for more than 28 days of therapy. In the Phase 3 trial, there were a total of 14 adult patients who were treated with daptomycin for injection for more than 28 days.</paragraph>
                     </text>
                     <effectiveTime value="20220818"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="1c7f47d7-caf5-41e4-b80f-9bc8b1915dd5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4	Dosage in Patients with Renal Impairment</title>
                     <effectiveTime value="20250228"/>
                     <component>
                        <section ID="ID_a82052af-b03d-4496-94a4-b01b72dd5d1c">
                           <id root="ea62ae5f-6e34-4449-bd4f-1d9319f7cbd2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adult Patients:</content>
                              </paragraph>
                              <paragraph>No dosage adjustment is required in adult patients with creatinine clearance (CL<sub>CR</sub>) greater than or equal to 30 mL/min. The recommended dosage regimen for Daptomycin for Injection in adult patients with CL<sub>CR</sub> less than 30 mL/min, including adult patients on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD), is 4 mg/kg (cSSSI) or 6 mg/kg (<content styleCode="italics">S. aureus</content> bloodstream infections) once every 48 hours (Table 1). When possible, Daptomycin for Injection should be administered following the completion of hemodialysis on hemodialysis days <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2</linkHtml>, <linkHtml href="#S5.10">5.10)</linkHtml>, <linkHtml href="#S8.6">Use in Specific Populations (8.6)</linkHtml>, and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                              <table ID="_Reftable1" width="85%">
                                 <caption>Table 1: Recommended Dosage of Daptomycin for Injection in Adult Patients</caption>
                                 <col width="33%"/>
                                 <col width="33%"/>
                                 <col width="33%"/>
                                 <thead>
                                    <tr>
                                       <th align="left" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <content styleCode="bold">Creatinine Clearance (CL<sub>CR</sub>)</content>
                                       </th>
                                       <th align="center" colspan="2" styleCode="Rrule Botrule Toprule " valign="top">
                                          <content styleCode="bold">Dosage Regimen in Adults</content>
                                       </th>
                                    </tr>
                                    <tr>
                                       <th align="center" styleCode="Rrule Botrule " valign="top">
                                          <content styleCode="bold">cSSSI</content>
                                       </th>
                                       <th align="center" styleCode="Rrule Botrule " valign="top">
                                          <content styleCode="bold">
                                             <content styleCode="italics">S. aureus</content> Bloodstream Infections</content>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>Greater than or equal to 30 mL/min</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                          <paragraph>4 mg/kg once every 24 hours</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                          <paragraph>6 mg/kg once every 24 hours</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Botrule Lrule " valign="top">
                                          <paragraph>Less than 30 mL/min, including hemodialysis and CAPD</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>4 mg/kg once every 48 hours<footnote ID="_Reffoot1">When possible, administer Daptomycin for Injection following the completion of hemodialysis on hemodialysis days.</footnote>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>6 mg/kg once every 48 hours<footnoteRef IDREF="_Reffoot1"/>
                                          </paragraph>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250228"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_042abe71-1e2a-48a2-850a-fb3007c756e1">
                           <id root="3c5da95a-ad0d-4a64-9994-7df26417cc7c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pediatric Patients:</content>
                              </paragraph>
                              <paragraph>The dosage regimen for Daptomycin for Injection in pediatric patients with renal impairment has not been established.</paragraph>
                           </text>
                           <effectiveTime value="20220818"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.5">
                     <id root="abb4ced3-b307-47e3-b978-ac1ed7aff49d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5	Preparation and Administration of Daptomycin for Injection </title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">There are other formulations of daptomycin that have differences concerning reconstitution and storage. Carefully follow the reconstitution and storage procedures described in this labeling.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220818"/>
                     <component>
                        <section ID="ID_1cc6c3e2-e58e-45b1-b16d-8e88c1128369">
                           <id root="17b07e15-9c79-4b03-b1a2-9d57ae4ff85a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Reconstitution of Daptomycin for Injection Vial</content>
                              </paragraph>
                              <paragraph>Daptomycin for Injection is supplied in single-dose vials, each containing 350 mg or 500 mg daptomycin as a sterile, lyophilized powder. The contents of a Daptomycin for Injection vial should be reconstituted, using aseptic technique, to 50 mg/mL as follows:</paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>To minimize foaming, AVOID vigorous agitation or shaking of the vial during or after reconstitution.</item>
                                 <item>
                                    <caption>•</caption>Remove the polypropylene flip-off cap from the Daptomycin for Injection vial to expose the central portion of the rubber stopper. Wipe the top of the rubber stopper with an alcohol swab or other antiseptic solution and allow to dry.</item>
                                 <item>
                                    <caption>•</caption>Pierce the center of the rubber stopper with the syringe needle and GENTLY inject 10 mL of 0.9% sodium chloride injection directly over the Daptomycin for Injection 500 mg drug product or 7 mL of 0.9% sodium chloride injection directly over the Daptomycin for Injection 350 mg drug product. Release the syringe plunger and allow the syringe plunger to equalize the pressure before removing the syringe from the vial.</item>
                                 <item>
                                    <caption>•</caption>Hold the vial by the vial neck, tilt the vial and swirl vial contents until the product is completely reconstituted.</item>
                              </list>
                           </text>
                           <effectiveTime value="20220818"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_bae26bce-c111-4fc7-a42a-a09d90effafd">
                           <id root="c2b5c193-80e9-4cb0-9c35-231f2e9c0f17"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Administration Instructions</content>
                              </paragraph>
                              <paragraph>Parenteral drug products should be inspected visually for particulate matter prior to administration.</paragraph>
                              <paragraph>Slowly remove reconstituted liquid (concentration of 50 mg daptomycin/mL) from the vial using a beveled sterile needle that is 21 gauge or smaller in diameter. Administer as an intravenous injection or infusion as described below:</paragraph>
                           </text>
                           <effectiveTime value="20220818"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_f1a226d0-8002-4c3b-8f93-c5b1991e5f08">
                           <id root="498f94b6-b79d-4141-bd32-f334cc8bde4b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adults</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20220818"/>
                           <component>
                              <section ID="ID_9c70fb66-a1e9-42e8-890d-6cb839df1109">
                                 <id root="58b232f8-6575-4bc2-bbc9-a1915ef52d8e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Intravenous Injection over a period of 2 minutes</content>
                                    </paragraph>
                                    <list listType="unordered">
                                       <item>
                                          <caption>•</caption>For intravenous (IV) injection over a period of 2 minutes in adult patients only: Administer the appropriate volume of the reconstituted Daptomycin for Injection (concentration of 50 mg/mL).</item>
                                    </list>
                                 </text>
                                 <effectiveTime value="20220818"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_06dec270-8fe8-4104-abe5-16ab81ef5b48">
                                 <id root="e7214c79-b354-4f85-8dcb-37d395107252"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Intravenous Infusion over a period of 30 minutes</content>
                                    </paragraph>
                                    <list listType="unordered">
                                       <item>
                                          <caption>•</caption>For IV infusion over a period of 30 minutes in adult patients: The appropriate volume of the reconstituted Daptomycin for Injection (concentration of 50 mg/mL) should be further diluted, using aseptic technique, into a 50 mL IV infusion bag containing 0.9% sodium chloride injection.</item>
                                    </list>
                                    <paragraph>No preservative or bacteriostatic agent is present in this product. Aseptic technique must be used in the preparation of final IV solution. Do not exceed the In-Use storage conditions of the reconstituted and diluted solutions of Daptomycin for Injection described below. Discard unused portions of Daptomycin for Injection.</paragraph>
                                 </text>
                                 <effectiveTime value="20220818"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_d9d1f644-58f3-4073-a1e3-23c5c16b32e7">
                           <id root="424a2ad5-9268-43e1-86b0-0bb0dffba2ed"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">In-Use Storage Conditions for Daptomycin for Injection Once Reconstituted in Acceptable Intravenous Diluents</content>
                              </paragraph>
                              <paragraph>Stability studies have shown that the reconstituted solution is stable in the vial for 12 hours at room temperature under normal room light and up to 48 hours if stored under refrigeration protected from light at 2°C to 8°C (36°F to 46°F).</paragraph>
                              <paragraph>The diluted solution is stable in the infusion bag for 12 hours under normal room light at room temperature and 48 hours (Lactated Ringer's) or 10 days (0.9% sodium chloride) if stored under refrigeration protected from light. </paragraph>
                              <paragraph>For Lactated Ringer's diluent, the combined storage time (reconstituted solution in vial and diluted solution in infusion bag) should not exceed 12 hours at room temperature or 48 hours under refrigeration. </paragraph>
                              <paragraph>For 0.9% sodium chloride diluent, the combined storage time (reconstituted solution in vial and diluted solution in infusion bag) should not exceed 12 hours at room temperature or 10 days under refrigeration.</paragraph>
                           </text>
                           <effectiveTime value="20220818"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.6">
                     <id root="b679877d-7c30-4a62-b57d-d3cf94799c06"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6	Compatible Intravenous Solutions</title>
                     <text>
                        <paragraph>Daptomycin for Injection is compatible with 0.9% sodium chloride injection for reconstitution. Reconstituted Daptomycin for Injection can be diluted with 0.9% sodium chloride injection or Lactated Ringer's injection.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.7">
                     <id root="8dcae89f-6336-42c3-b347-937df76cf34a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.7	Incompatibilities</title>
                     <text>
                        <paragraph>Daptomycin for injection is not compatible with dextrose-containing diluents.</paragraph>
                        <paragraph>Daptomycin for Injection should not be used in conjunction with ReadyMED<sup>®</sup> elastomeric infusion pumps. Stability studies of daptomycin for injection solutions stored in ReadyMED<sup>®</sup> elastomeric infusion pumps identified an impurity (2-mercaptobenzothiazole) leaching from this pump system into the daptomycin for injection solution.</paragraph>
                        <paragraph>Because only limited data are available on the compatibility of daptomycin for injection with other IV substances, additives and other medications should not be added to Daptomycin for Injection single-dose vials or infusion bags, or infused simultaneously with Daptomycin for Injection through the same IV line. If the same IV line is used for sequential infusion of different drugs, the line should be flushed with a compatible intravenous solution before and after infusion with Daptomycin for Injection.</paragraph>
                     </text>
                     <effectiveTime value="20220818"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="2bab1690-aae9-4bc5-93be-c0687f512b24"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>For Injection: 350 mg and 500 mg daptomycin as a sterile, pale yellow to light brown lyophilized powder for reconstitution in a single-dose vial.</paragraph>
               </text>
               <effectiveTime value="20220818"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>350 mg lyophilized powder for reconstitution in a single-dose vial (<linkHtml href="#S3">3</linkHtml>)</item>
                           <item>
                              <caption>•</caption>500 mg lyophilized powder for reconstitution in a single-dose vial (<linkHtml href="#S3">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="4fc758bd-f1a5-4c7c-93c2-d35706a10d1d"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Daptomycin for Injection is contraindicated in patients with known hypersensitivity to daptomycin <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
               </text>
               <effectiveTime value="20220818"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Known hypersensitivity to daptomycin (<linkHtml href="#S4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="179b16fd-193c-4a73-b198-9b121864c747"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Anaphylaxis/hypersensitivity reactions (including life-threatening): Discontinue Daptomycin for Injection and treat sign/symptoms. (<linkHtml href="#S5.1">5.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Myopathy and rhabdomyolysis: Monitor CPK levels and follow muscle pain or weakness; if elevated CPK or myopathy occurs, consider discontinuation of Daptomycin for Injection. (<linkHtml href="#S5.2">5.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Eosinophilic pneumonia: Discontinue Daptomycin for Injection and consider treatment with systemic steroids. (<linkHtml href="#S5.3">5.3</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Discontinue Daptomycin for Injection and institute appropriate treatment. (<linkHtml href="#S5.4">5.4</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Tubulointerstitial Nephritis (TIN): Discontinue Daptomycin for Injection and institute appropriate treatment. (<linkHtml href="#S5.5">5.5</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Peripheral neuropathy: Monitor for neuropathy and consider discontinuation. (<linkHtml href="#S5.6">5.6</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Potential nervous system and/or muscular system effects in pediatric patients younger than 12 months: Avoid use of Daptomycin for Injection in this age group. (<linkHtml href="#S5.7">5.7</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="italics">Clostridioides difficile–</content>associated diarrhea: Evaluate patients if diarrhea occurs. (<linkHtml href="#S5.8">5.8</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Persisting or relapsing <content styleCode="italics">S. aureus</content> bacteremia/endocarditis: Perform susceptibility testing and rule out sequestered foci of infection. (<linkHtml href="#S5.9">5.9</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Decreased efficacy was observed in adult patients with moderate baseline renal impairment. (<linkHtml href="#S5.10">5.10</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="b9364f4f-1dc8-46cb-99fe-39b91129e30d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	Anaphylaxis/Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>Anaphylaxis/hypersensitivity reactions have been reported with the use of antibacterial agents, including daptomycin for injection, and may be life-threatening. If an allergic reaction to Daptomycin for Injection occurs, discontinue the drug and institute appropriate therapy <content styleCode="italics">[see <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20220818"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="23f25ed4-47d1-40e6-9973-bf226e85da3c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2	Myopathy and Rhabdomyolysis</title>
                     <text>
                        <paragraph>Myopathy, defined as muscle aching or muscle weakness in conjunction with increases in creatine phosphokinase (CPK) values to greater than 10 times the upper limit of normal (ULN), has been reported with the use of daptomycin for injection. Rhabdomyolysis, with or without acute renal failure, has been reported <content styleCode="italics">[see <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>]</content>.</paragraph>
                        <paragraph>Patients receiving Daptomycin for Injection should be monitored for the development of muscle pain or weakness, particularly of the distal extremities. In patients who receive Daptomycin for Injection, CPK levels should be monitored weekly, and more frequently in patients who received recent prior or concomitant therapy with an HMG-CoA reductase inhibitor or in whom elevations in CPK occur during treatment with Daptomycin for Injection. </paragraph>
                        <paragraph>In adult patients with renal impairment, both renal function and CPK should be monitored more frequently than once weekly <content styleCode="italics">[see <linkHtml href="#S8.6">Use in Specific Populations (8.6)</linkHtml> and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>In Phase 1 studies and Phase 2 clinical trials in adults, CPK elevations appeared to be more frequent when daptomycin for injection was dosed more than once daily. Therefore, Daptomycin for Injection should not be dosed more frequently than once a day.</paragraph>
                        <paragraph>Daptomycin for Injection should be discontinued in patients with unexplained signs and symptoms of myopathy in conjunction with CPK elevations to levels &gt;1,000 U/L (~5× ULN), and in patients without reported symptoms who have marked elevations in CPK, with levels &gt;2,000 U/L (≥10× ULN). In addition, consideration should be given to suspending agents associated with rhabdomyolysis, such as HMG-CoA reductase inhibitors, temporarily in patients receiving Daptomycin for Injection <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220818"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="486ee6ed-80f1-4e59-851e-8012b7d2115e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3	Eosinophilic Pneumonia</title>
                     <text>
                        <paragraph>Eosinophilic pneumonia has been reported in patients receiving daptomycin for injection <content styleCode="italics">[see <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>]</content>. In reported cases associated with daptomycin for injection, patients developed fever, dyspnea with hypoxic respiratory insufficiency, and diffuse pulmonary infiltrates or organizing pneumonia. In general, patients developed eosinophilic pneumonia 2 to 4 weeks after starting daptomycin for injection, and improved when daptomycin for injection was discontinued and steroid therapy was initiated. Recurrence of eosinophilic pneumonia upon re-exposure has been reported. Patients who develop these signs and symptoms while receiving Daptomycin for Injection should undergo prompt medical evaluation, and Daptomycin for Injection should be discontinued immediately. Treatment with systemic steroids is recommended.</paragraph>
                     </text>
                     <effectiveTime value="20220818"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="9fddf886-f0c7-40ff-a866-78929f0311a9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)</title>
                     <text>
                        <paragraph>DRESS has been reported in post-marketing experience with daptomycin for injection <content styleCode="italics">[see <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>]</content>. Patients who develop skin rash, fever, peripheral eosinophilia, and systemic organ (for example, hepatic, renal, pulmonary) impairment while receiving Daptomycin for Injection should undergo medical evaluation. If DRESS is suspected, discontinue Daptomycin for Injection promptly and institute appropriate treatment. </paragraph>
                     </text>
                     <effectiveTime value="20220818"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="6e92533d-a464-49f5-aad1-f2945eaa5a18"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5	Tubulointerstitial Nephritis (TIN)</title>
                     <text>
                        <paragraph>TIN has been reported in post-marketing experience with daptomycin for injection <content styleCode="italics">[see <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>]</content>. Patients who develop new or worsening renal impairment while receiving Daptomycin for Injection should undergo medical evaluation. If TIN is suspected, discontinue Daptomycin for Injection promptly and institute appropriate treatment.</paragraph>
                     </text>
                     <effectiveTime value="20220818"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.6">
                     <id root="4a5a209e-7948-40af-b5e6-c26b500edd91"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6	Peripheral Neuropathy</title>
                     <text>
                        <paragraph>Cases of peripheral neuropathy have been reported during the daptomycin for injection post-marketing experience <content styleCode="italics">[see <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>].</content> Therefore, physicians should be alert to signs and symptoms of peripheral neuropathy in patients receiving Daptomycin for Injection. Monitor for neuropathy and consider discontinuation.</paragraph>
                     </text>
                     <effectiveTime value="20220818"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.7">
                     <id root="85fd162e-1b9b-4021-a79f-dbb885b54b33"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7	Potential Nervous System and/or Muscular System Effects in Pediatric Patients Younger than 12 Months</title>
                     <text>
                        <paragraph>Avoid use of Daptomycin for Injection in pediatric patients younger than 12 months due to the risk of potential effects on muscular, neuromuscular, and/or nervous systems (either peripheral and/or central) observed in neonatal dogs with intravenous daptomycin <content styleCode="italics">[see <linkHtml href="#S13.2">Nonclinical Toxicology (13.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220818"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.8">
                     <id root="9c1fad66-4029-4898-beea-46ab15fc5300"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8	<content styleCode="italics">Clostridioides difficile</content>-Associated Diarrhea</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Clostridioides difficile</content>–associated diarrhea (CDAD) has been reported with the use of nearly all systemic antibacterial agents, including daptomycin for injection, and may range in severity from mild diarrhea to fatal colitis <content styleCode="italics">[see <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>].</content> Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of <content styleCode="italics">C. difficile</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">C. difficile</content> produces toxins A and B, which contribute to the development of CDAD. Hypertoxin-producing strains of <content styleCode="italics">C. difficile</content> cause increased morbidity and mortality, since these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical history is necessary because CDAD has been reported to occur more than 2 months after the administration of antibacterial agents.</paragraph>
                        <paragraph>If CDAD is suspected or confirmed, ongoing antibacterial use not directed against <content styleCode="italics">C. difficile</content> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of <content styleCode="italics">C. difficile</content>, and surgical evaluation should be instituted as clinically indicated.</paragraph>
                     </text>
                     <effectiveTime value="20220818"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.9">
                     <id root="0e0bc0d2-c2ab-441a-b6b7-6e0667945f1e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9	Persisting or Relapsing <content styleCode="italics">S. aureus</content> Bacteremia/Endocarditis</title>
                     <text>
                        <paragraph>Patients with persisting or relapsing <content styleCode="italics">S. aureus</content> bacteremia/endocarditis or poor clinical response should have repeat blood cultures. If a blood culture is positive for <content styleCode="italics">S. aureus</content>, minimum inhibitory concentration (MIC) susceptibility testing of the isolate should be performed using a standardized procedure, and diagnostic evaluation of the patient should be performed to rule out sequestered foci of infection. Appropriate surgical intervention (e.g., debridement, removal of prosthetic devices, valve replacement surgery) and/or consideration of a change in antibacterial regimen may be required.</paragraph>
                        <paragraph>Failure of treatment due to persisting or relapsing <content styleCode="italics">S. aureus</content> bacteremia/endocarditis may be due to reduced daptomycin susceptibility (as evidenced by increasing MIC of the <content styleCode="italics">S. aureus</content> isolate) <content styleCode="italics">[see <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220818"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.10">
                     <id root="006d6e68-c0a8-41d0-a2a7-b5f0c6d5ae05"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10	Decreased Efficacy in Patients with Moderate Baseline Renal Impairment</title>
                     <text>
                        <paragraph>Limited data are available from the two Phase 3 complicated skin and skin structure infection (cSSSI) trials regarding clinical efficacy of daptomycin for injection treatment in adult patients with creatinine clearance (CL<sub>CR</sub>) &lt;50 mL/min; only 31/534 (6%) patients treated with daptomycin for injection in the intent-to-treat (ITT) population had a baseline CL<sub>CR</sub> &lt;50 mL/min. Table 2 shows the number of adult patients by renal function and treatment group who were clinical successes in the Phase 3 cSSSI trials.</paragraph>
                        <table ID="_Reftable2" width="85%">
                           <caption>Table 2: Clinical Success Rates by Renal Function and Treatment Group in Phase 3 cSSSI Trials in Adult Patients (Population: ITT)</caption>
                           <col width="33%"/>
                           <col width="33%"/>
                           <col width="33%"/>
                           <thead>
                              <tr>
                                 <th align="left" rowspan="2" styleCode="Rrule Lrule Toprule " valign="middle">
                                    <content styleCode="bold">CL<sub>CR</sub>
                                    </content>
                                 </th>
                                 <th align="center" colspan="2" styleCode="Rrule Botrule Toprule " valign="top">
                                    <content styleCode="bold">Success Rate n/N (%)</content>
                                 </th>
                              </tr>
                              <tr>
                                 <th align="center" styleCode="Rrule Botrule " valign="top">
                                    <content styleCode="bold">Daptomycin for Injection 4 mg/kg every 24h</content>
                                 </th>
                                 <th align="center" styleCode="Rrule Botrule " valign="top">
                                    <content styleCode="bold">Comparator</content>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>50–70 mL/min</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                    <paragraph>25/38 (66%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                    <paragraph>30/48 (63%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>30–&lt;50 mL/min</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>7/15 (47%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>20/35 (57%)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In a subgroup analysis of the ITT population in the Phase 3 <content styleCode="italics">S. aureus</content> bacteremia/endocarditis trial, clinical success rates, as determined by a treatment-blinded Adjudication Committee <content styleCode="italics">[see <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>]</content>, in the daptomycin for injection-treated adult patients were lower in patients with baseline CL<sub>CR</sub> &lt;50 mL/min (see <linkHtml href="#_Reftable3">Table 3</linkHtml>). A decrease of the magnitude shown in Table 3 was not observed in comparator-treated patients.</paragraph>
                        <table ID="_Reftable3" width="85%">
                           <caption>Table 3: Adjudication Committee Clinical Success Rates at Test of Cure by Baseline Creatinine Clearance and Treatment Subgroup in the S. aureus Bacteremia/Endocarditis Trial in Adult Patients (Population: ITT)</caption>
                           <col width="19%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <thead>
                              <tr>
                                 <th align="left" rowspan="3" styleCode="Rrule Lrule Toprule " valign="middle">
                                    <content styleCode="bold">Baseline CL<sub>CR</sub>
                                    </content>
                                 </th>
                                 <th align="center" colspan="4" styleCode="Rrule Botrule Toprule " valign="middle">
                                    <content styleCode="bold">Success Rate n/N (%)</content>
                                 </th>
                              </tr>
                              <tr>
                                 <th align="center" colspan="2" styleCode="Rrule Botrule " valign="middle">
                                    <content styleCode="bold">Daptomycin for Injection 6 mg/kg every 24h</content>
                                 </th>
                                 <th align="center" colspan="2" styleCode="Rrule Botrule " valign="middle">
                                    <content styleCode="bold">Comparator</content>
                                 </th>
                              </tr>
                              <tr>
                                 <th align="center" styleCode="Rrule Botrule " valign="bottom">
                                    <content styleCode="bold">Bacteremia</content>
                                 </th>
                                 <th align="center" styleCode="Rrule Botrule " valign="bottom">
                                    <content styleCode="bold">Right-Sided Infective Endocarditis</content>
                                 </th>
                                 <th align="center" styleCode="Rrule Botrule " valign="bottom">
                                    <content styleCode="bold">Bacteremia</content>
                                 </th>
                                 <th align="center" styleCode="Rrule Botrule " valign="bottom">
                                    <content styleCode="bold">Right-Sided Infective Endocarditis</content>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>&gt;80 mL/min</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="middle">
                                    <paragraph>30/50 (60%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="middle">
                                    <paragraph>7/14 (50%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="middle">
                                    <paragraph>19/42 (45%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="middle">
                                    <paragraph>5/11 (46%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>50–80 mL/min</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>12/26 (46%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>1/4 (25%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>13/31 (42%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>1/2 (50%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>30–&lt;50 mL/min</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>2/14 (14%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>0/1 (0%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>7/17 (41%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>1/1 (100%)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Consider these data when selecting antibacterial therapy for use in adult patients with baseline moderate to severe renal impairment.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.11">
                     <id root="3f5238fc-b21b-41a7-9dbc-f55119c63693"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.11	Increased International Normalized Ratio (INR)/Prolonged Prothrombin Time</title>
                     <text>
                        <paragraph>Clinically relevant plasma concentrations of daptomycin have been observed to cause a significant concentration-dependent false prolongation of prothrombin time (PT) and elevation of International Normalized Ratio (INR) when certain recombinant thromboplastin reagents are utilized for the assay <content styleCode="italics">[see <linkHtml href="#S7.2">Drug Interactions (7.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20220818"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.12">
                     <id root="60bc3cea-31d0-419b-b582-4ac5bcdc891f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.12	Development of Drug-Resistant Bacteria</title>
                     <text>
                        <paragraph>Prescribing Daptomycin for Injection in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="67a60734-e9ba-4d96-b226-335f26a4a951"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions are described, or described in greater detail, in other sections:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Anaphylaxis/Hypersensitivity Reactions <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Myopathy and Rhabdomyolysis <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Eosinophilic Pneumonia <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Drug Reaction with Eosinophilia and Systemic Symptoms <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Tubulointerstitial Nephritis <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Peripheral Neuropathy <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Increased International Normalized Ratio (INR)/Prolonged Prothrombin Time <content styleCode="italics">[see <linkHtml href="#S5.11">Warnings and Precautions (5.11)</linkHtml> and <linkHtml href="#S7.2">Drug Interactions (7.2)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Adult cSSSI Patients</content>: The most common adverse reactions that occurred in ≥2% of adult cSSSI patients receiving daptomycin for injection 4 mg/kg were diarrhea, headache, dizziness, rash, abnormal liver function tests, elevated creatine phosphokinase (CPK), urinary tract infections hypotension, and dyspnea. (<linkHtml href="#S6.1">6.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Adult <content styleCode="italics">S. aureus</content> bacteremia/endocarditis Patients:</content> The most common adverse reactions that occurred in ≥5% of <content styleCode="italics">S. aureus</content> bacteremia/endocarditis patients receiving daptomycin for injection 6 mg/kg were sepsis, bacteremia, abdominal pain, chest pain, edema, pharyngolaryngeal pain, pruritus, increased sweating, insomnia, elevated CPK, and hypertension. (<linkHtml href="#S6.1">6.1</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Hospira at 1-800-438-1985 or FDA at 1-800-FDA-1088 or <linkHtml href="https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program?os=avefgi&amp;ref=app">www.fda.gov/medwatch</linkHtml>.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="6df412c3-68dd-4619-bd31-55f1f13fe790"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                     <component>
                        <section ID="ID_b358cddc-3d6b-4a27-aec7-bf83c514fc99">
                           <id root="7e17b962-85de-4e74-92de-e0f77e2b2f52"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="underline">Clinical Trial Experience in Adult Patients</content>
                                 </content>
                              </paragraph>
                              <paragraph>Clinical trials enrolled 1,864 adult patients treated with daptomycin and 1,416 treated with comparator.</paragraph>
                           </text>
                           <effectiveTime value="20250228"/>
                           <component>
                              <section ID="ID_5d2c82f2-2faa-4405-bfd1-3c25c5202c5d">
                                 <id root="d46e471d-b549-4984-b39f-20b3fcd60407"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline">Complicated Skin and Skin Structure Infection Trials in Adults</content>
                                    </paragraph>
                                    <paragraph>In Phase 3 complicated skin and skin structure infection (cSSSI) trials in adult patients, daptomycin for injection was discontinued in 15/534 (2.8%) patients due to an adverse reaction, while comparator was discontinued in 17/558 (3.0%) patients.</paragraph>
                                    <paragraph>The rates of the most common adverse reactions, organized by body system, observed in adult patients with cSSSI (receiving 4 mg/kg daptomycin) are displayed in Table 4.</paragraph>
                                    <table ID="_Reftable4" width="85%">
                                       <caption>Table 4: Incidence of Adverse Reactions that Occurred in ≥2% of Adult Patients in the Daptomycin for Injection Treatment Group and ≥ the Comparator Treatment Group in Phase 3 cSSSI Trials</caption>
                                       <col width="33%"/>
                                       <col width="33%"/>
                                       <col width="33%"/>
                                       <thead>
                                          <tr>
                                             <th align="left" rowspan="2" styleCode="Rrule Lrule Toprule " valign="middle">
                                                <content styleCode="bold">Adverse Reaction</content>
                                             </th>
                                             <th align="center" colspan="2" styleCode="Rrule Botrule Toprule " valign="middle">
                                                <content styleCode="bold">Adult Patients n (%)</content>
                                             </th>
                                          </tr>
                                          <tr>
                                             <th align="center" styleCode="Rrule Botrule " valign="top">
                                                <content styleCode="bold">Daptomycin for Injection 4 mg/kg (N=534)</content>
                                             </th>
                                             <th align="center" styleCode="Rrule Botrule " valign="middle">
                                                <content styleCode="bold">Comparator</content>
                                                <footnote ID="_RefID0EQJAG">Comparator: vancomycin (1 g IV every 12h) or an anti-staphylococcal semi-synthetic penicillin (i.e., nafcillin, oxacillin, cloxacillin, or flucloxacillin; 4 to 12 g/day IV in divided doses).</footnote>
                                                <br/>
                                                <content styleCode="bold">(N=558)</content>
                                             </th>
                                          </tr>
                                       </thead>
                                       <tbody>
                                          <tr>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                                <paragraph>
                                                   <content styleCode="bold">Gastrointestinal disorders</content>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Toprule Botrule " valign="middle"/>
                                             <td styleCode="Rrule Toprule Botrule " valign="middle"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="middle">
                                                <paragraph>  Diarrhea</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="middle">
                                                <paragraph>5.2</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="middle">
                                                <paragraph>4.3</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="middle">
                                                <paragraph>
                                                   <content styleCode="bold">Nervous system disorders</content>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Botrule " valign="middle"/>
                                             <td styleCode="Rrule Botrule " valign="middle"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="middle">
                                                <paragraph>  Headache</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="middle">
                                                <paragraph>5.4</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="middle">
                                                <paragraph>5.4</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="middle">
                                                <paragraph>  Dizziness</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="middle">
                                                <paragraph>2.2</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="middle">
                                                <paragraph>2.0</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="middle">
                                                <paragraph>
                                                   <content styleCode="bold">Skin/subcutaneous disorders</content>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Botrule " valign="middle"/>
                                             <td styleCode="Rrule Botrule " valign="middle"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="middle">
                                                <paragraph>  Rash</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="middle">
                                                <paragraph>4.3</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="middle">
                                                <paragraph>3.8</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="middle">
                                                <paragraph>
                                                   <content styleCode="bold">Diagnostic investigations</content>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Botrule " valign="middle"/>
                                             <td styleCode="Rrule Botrule " valign="middle"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="middle">
                                                <paragraph>  Abnormal liver function tests</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="middle">
                                                <paragraph>3.0</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="middle">
                                                <paragraph>1.6</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="middle">
                                                <paragraph>  Elevated CPK</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="middle">
                                                <paragraph>2.8</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="middle">
                                                <paragraph>1.8</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="middle">
                                                <paragraph>
                                                   <content styleCode="bold">Infections</content>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Botrule " valign="middle"/>
                                             <td styleCode="Rrule Botrule " valign="middle"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="middle">
                                                <paragraph>  Urinary tract infections</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="middle">
                                                <paragraph>2.4</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="middle">
                                                <paragraph>0.5</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="middle">
                                                <paragraph>
                                                   <content styleCode="bold">Vascular disorders</content>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Botrule " valign="middle"/>
                                             <td styleCode="Rrule Botrule " valign="middle"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="middle">
                                                <paragraph>  Hypotension</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="middle">
                                                <paragraph>2.4</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="middle">
                                                <paragraph>1.4</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="middle">
                                                <paragraph>
                                                   <content styleCode="bold">Respiratory disorders</content>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Botrule " valign="middle"/>
                                             <td styleCode="Rrule Botrule " valign="middle"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Botrule Lrule " valign="middle">
                                                <paragraph>  Dyspnea</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="middle">
                                                <paragraph>2.1</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="middle">
                                                <paragraph>1.6</paragraph>
                                             </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <paragraph>Drug-related adverse reactions (possibly or probably drug-related) that occurred in &lt;1% of adult patients receiving daptomycin in the cSSSI trials are as follows:</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Body as a Whole:</content> fatigue, weakness, rigors, flushing, hypersensitivity</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Blood/Lymphatic System:</content> leukocytosis, thrombocytopenia, thrombocytosis, eosinophilia, increased International Normalized Ratio (INR)</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Cardiovascular System:</content> supraventricular arrhythmia</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Dermatologic System:</content> eczema</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Digestive System:</content> abdominal distension, stomatitis, jaundice, increased serum lactate dehydrogenase </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Metabolic/Nutritional System:</content> hypomagnesemia, increased serum bicarbonate, electrolyte disturbance</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Musculoskeletal System:</content> myalgia, muscle cramps, muscle weakness, arthralgia</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Nervous System:</content> vertigo, mental status change, paresthesia</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Special Senses:</content> taste disturbance, eye irritation</paragraph>
                                 </text>
                                 <effectiveTime value="20250228"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_27cf6379-64fa-4597-8b55-3fae02e309e6">
                                 <id root="8b420a42-f868-4622-99db-44540b35524c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline">
                                          <content styleCode="italics">S. aureus</content> Bacteremia/Endocarditis Trial in Adults</content>
                                    </paragraph>
                                    <paragraph>In the <content styleCode="italics">S. aureus</content> bacteremia/endocarditis trial involving adult patients, daptomycin for injection was discontinued in 20/120 (16.7%) patients due to an adverse reaction, while comparator was discontinued in 21/116 (18.1%) patients.</paragraph>
                                    <paragraph>Serious Gram-negative infections (including bloodstream infections) were reported in 10/120 (8.3%) daptomycin for injection-treated patients and 0/115 comparator-treated patients. Comparator-treated patients received dual therapy that included initial gentamicin for 4 days. Infections were reported during treatment and during early and late follow-up. Gram-negative infections included cholangitis, alcoholic pancreatitis, sternal osteomyelitis/mediastinitis, bowel infarction, recurrent Crohn's disease, recurrent line sepsis, and recurrent urosepsis caused by a number of different Gram-negative bacteria.</paragraph>
                                    <paragraph>The rates of the most common adverse reactions, organized by System Organ Class (SOC), observed in adult patients with <content styleCode="italics">S. aureus</content> bacteremia/endocarditis (receiving 6 mg/kg daptomycin) are displayed in Table 5.</paragraph>
                                    <table ID="_Reftable5" width="85%">
                                       <caption>Table 5: Incidence of Adverse Reactions that Occurred in ≥5% of Adult Patients in the Daptomycin for Injection Treatment Group and ≥ the Comparator Treatment Group in the S. aureus Bacteremia/Endocarditis Trial</caption>
                                       <col width="33%"/>
                                       <col width="33%"/>
                                       <col width="33%"/>
                                       <thead>
                                          <tr>
                                             <th align="left" rowspan="2" styleCode="Rrule Lrule Toprule " valign="middle">
                                                <content styleCode="bold">Adverse Reaction</content>
                                                <footnote ID="_RefID0E1QAG">NOS, not otherwise specified</footnote>
                                             </th>
                                             <th align="center" colspan="2" styleCode="Rrule Botrule Toprule " valign="top">
                                                <content styleCode="bold">Adult Patients n (%)</content>
                                             </th>
                                          </tr>
                                          <tr>
                                             <th align="center" styleCode="Rrule Botrule " valign="top">
                                                <content styleCode="bold">Daptomycin for Injection</content>
                                                <br/>
                                                <content styleCode="bold">6 mg/kg (N=120)</content>
                                             </th>
                                             <th align="center" styleCode="Rrule Botrule " valign="top">
                                                <content styleCode="bold">Comparator</content>
                                                <footnote ID="_RefID0EIRAG">Comparator: vancomycin (1 g IV every 12h) or an anti-staphylococcal semi-synthetic penicillin (i.e., nafcillin, oxacillin, cloxacillin, or flucloxacillin; 2 g IV every 4h), each with initial low-dose gentamicin.</footnote>
                                                <content styleCode="bold"> (N=116)</content>
                                             </th>
                                          </tr>
                                       </thead>
                                       <tbody>
                                          <tr>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Infections and infestations</content>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Toprule Botrule " valign="top"/>
                                             <td styleCode="Rrule Toprule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Sepsis NOS</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>6 (5%)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>3 (3%)</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Bacteremia</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>6 (5%)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>0 (0%)</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Gastrointestinal disorders</content>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Botrule " valign="top"/>
                                             <td styleCode="Rrule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Abdominal pain NOS</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>7 (6%)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>4 (3%)</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">General disorders and administration site conditions</content>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Botrule " valign="top"/>
                                             <td styleCode="Rrule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Chest pain</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>8 (7%)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>7 (6%)</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Edema NOS</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>8 (7%)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>5 (4%)</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Respiratory, thoracic and mediastinal disorders</content>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Botrule " valign="top"/>
                                             <td styleCode="Rrule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Pharyngolaryngeal pain</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>10 (8%)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>2 (2%)</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Skin and subcutaneous tissue disorders</content>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Botrule " valign="top"/>
                                             <td styleCode="Rrule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Pruritus</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>7 (6%)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>6 (5%)</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Sweating increased</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>6 (5%)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>0 (0%)</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Psychiatric disorders</content>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Botrule " valign="top"/>
                                             <td styleCode="Rrule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Insomnia</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>11 (9%)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>8 (7%)</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Investigations</content>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Botrule " valign="top"/>
                                             <td styleCode="Rrule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Blood creatine phosphokinase increased</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>8 (7%)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>1 (1%)</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Vascular disorders</content>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Botrule " valign="top"/>
                                             <td styleCode="Rrule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Botrule Lrule " valign="top">
                                                <paragraph>Hypertension NOS</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>7 (6%)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>3 (3%)</paragraph>
                                             </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <paragraph>The following reactions, not included above, were reported as possibly or probably drug-related in the daptomycin for injection-treated group:</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Blood and Lymphatic System Disorders:</content> eosinophilia, lymphadenopathy, thrombocythemia, thrombocytopenia</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Cardiac Disorders:</content> atrial fibrillation, atrial flutter, cardiac arrest</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Ear and Labyrinth Disorders:</content> tinnitus</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Eye Disorders:</content> vision blurred</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Gastrointestinal Disorders:</content> dry mouth, epigastric discomfort, gingival pain, hypoesthesia oral</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Infections and Infestations:</content> candidal infection NOS, vaginal candidiasis, fungemia, oral candidiasis, urinary tract infection fungal</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Investigations:</content> blood phosphorous increased, blood alkaline phosphatase increased, INR increased, liver function test abnormal, alanine aminotransferase increased, aspartate aminotransferase increased, prothrombin time prolonged</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Metabolism and Nutrition Disorders:</content> appetite decreased NOS </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Musculoskeletal and Connective Tissue Disorders:</content> myalgia </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Nervous System Disorders:</content> dyskinesia, paresthesia </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Psychiatric Disorders:</content> hallucination NOS</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Renal and Urinary Disorders:</content> proteinuria, renal impairment NOS</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Skin and Subcutaneous Tissue Disorders:</content> pruritus generalized, rash vesicular</paragraph>
                                 </text>
                                 <effectiveTime value="20250228"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_10f34cbd-e419-4b74-9cc9-94c493d6ae72">
                                 <id root="fa1a0673-fc52-45d9-92ee-3ab90cbc6144"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline">Other Trials in Adults</content>
                                    </paragraph>
                                    <paragraph>In Phase 3 trials of community-acquired pneumonia (CAP) in adult patients, the death rate and rates of serious cardiorespiratory adverse events were higher in daptomycin for injection-treated patients than in comparator-treated patients. These differences were due to lack of therapeutic effectiveness of daptomycin for injection in the treatment of CAP in patients experiencing these adverse events <content styleCode="italics">[see <linkHtml href="#S1.3">Indications and Usage (1.3)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20220818"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_8eabe905-5079-41e1-99eb-d25b29ba0de5">
                                 <id root="e4477936-cdd0-46ec-a872-4e6d6afeddc7"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline">Laboratory Changes in Adults</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250228"/>
                                 <component>
                                    <section ID="ID_d22eeb79-86d8-425a-8aea-774ac959850c">
                                       <id root="aed43705-0144-42db-8ee4-a16fa29b79ab"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Complicated Skin and Skin Structure Infection Trials in Adults</content>
                                          </paragraph>
                                          <paragraph>In Phase 3 cSSSI trials of adult patients receiving daptomycin for injection at a dose of 4 mg/kg, elevations in CPK were reported as clinical adverse events in 15/534 (2.8%) daptomycin for injection-treated patients, compared with 10/558 (1.8%) comparator-treated patients. Of the 534 patients treated with daptomycin, 1 (0.2%) had symptoms of muscle pain or weakness associated with CPK elevations to greater than 4 times the upper limit of normal (ULN). The symptoms resolved within 3 days and CPK returned to normal within 7 to 10 days after treatment was discontinued <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>. Table 6 summarizes the CPK shifts from Baseline through End of Therapy in the cSSSI adult trials.</paragraph>
                                          <table ID="_Reftable6" width="85%">
                                             <caption>Table 6: Incidence of CPK Elevations from Baseline during Therapy in Either the Daptomycin for Injection Treatment Group or the Comparator Treatment Group in Phase 3 cSSSI Adult Trials</caption>
                                             <col width="12%"/>
                                             <col width="9%"/>
                                             <col width="11%"/>
                                             <col width="9%"/>
                                             <col width="10%"/>
                                             <col width="9%"/>
                                             <col width="9%"/>
                                             <col width="9%"/>
                                             <col width="10%"/>
                                             <col width="9%"/>
                                             <thead>
                                                <tr>
                                                   <th align="center" colspan="2" rowspan="4" styleCode="Rrule Lrule Toprule " valign="middle">
                                                      <content styleCode="bold">Change in CPK</content>
                                                   </th>
                                                   <th align="right" colspan="4" styleCode="Rrule Botrule Toprule " valign="bottom">
                                                      <content styleCode="bold">All Adult Patients</content>
                                                   </th>
                                                   <th align="center" colspan="4" styleCode="Rrule Botrule Toprule " valign="top">
                                                      <content styleCode="bold">Adult Patients with Normal CPK at Baseline</content>
                                                   </th>
                                                </tr>
                                                <tr>
                                                   <th align="center" colspan="2" styleCode="Rrule " valign="top">
                                                      <content styleCode="bold">Daptomycin for Injection</content>
                                                      <br/>
                                                      <content styleCode="bold">4 mg/kg</content>
                                                   </th>
                                                   <th align="right" colspan="2" styleCode="Rrule " valign="top">
                                                      <content styleCode="bold">Comparator</content>
                                                      <footnote ID="_Reffoot6a">Comparator: vancomycin (1 g IV every 12h) or an anti-staphylococcal semi-synthetic penicillin (i.e., nafcillin, oxacillin, cloxacillin, or flucloxacillin; 4 to 12 g/day IV in divided doses).</footnote>
                                                      <br/>
                                                      <content styleCode="bold"> (N=459)</content>
                                                   </th>
                                                   <th align="center" colspan="2" styleCode="Rrule " valign="top">
                                                      <content styleCode="bold">Daptomycin for Injection </content>
                                                      <br/>
                                                      <content styleCode="bold">4 mg/kg </content>
                                                   </th>
                                                   <th align="center" colspan="2" styleCode="Rrule " valign="top">
                                                      <content styleCode="bold">Comparator</content>
                                                      <footnoteRef IDREF="_Reffoot6a"/>
                                                      <br/>
                                                      <content styleCode="bold"> (N=392)</content>
                                                   </th>
                                                </tr>
                                                <tr>
                                                   <th align="center" colspan="2" styleCode="Rrule " valign="top">
                                                      <content styleCode="bold">(N=430)</content>
                                                   </th>
                                                   <th align="right" valign="top">
                                                      <content styleCode="bold">%</content>
                                                   </th>
                                                   <th align="center" styleCode="Rrule " valign="top">
                                                      <content styleCode="bold">n</content>
                                                   </th>
                                                   <th align="center" colspan="2" styleCode="Rrule " valign="top">
                                                      <content styleCode="bold">(N=374)</content>
                                                   </th>
                                                   <th align="center" valign="top">
                                                      <content styleCode="bold">%</content>
                                                   </th>
                                                   <th align="center" styleCode="Rrule " valign="top">
                                                      <content styleCode="bold">n</content>
                                                   </th>
                                                </tr>
                                                <tr>
                                                   <th align="center" styleCode="Botrule " valign="bottom">
                                                      <content styleCode="bold">%</content>
                                                   </th>
                                                   <th align="center" styleCode="Rrule Botrule " valign="bottom">
                                                      <content styleCode="bold">n</content>
                                                   </th>
                                                   <th align="left" styleCode="Botrule " valign="top"/>
                                                   <th align="left" styleCode="Rrule Botrule " valign="top"/>
                                                   <th align="center" styleCode="Botrule " valign="bottom">
                                                      <content styleCode="bold">%</content>
                                                   </th>
                                                   <th align="center" styleCode="Rrule Botrule " valign="bottom">
                                                      <content styleCode="bold">n</content>
                                                   </th>
                                                   <th align="left" styleCode="Botrule " valign="top"/>
                                                   <th align="left" styleCode="Rrule Botrule " valign="top"/>
                                                </tr>
                                             </thead>
                                             <tfoot>
                                                <tr>
                                                   <td align="left" colspan="10" valign="top">Note: Elevations in CPK observed in adult patients treated with daptomycin for injection or comparator were not clinically or statistically significantly different.</td>
                                                </tr>
                                             </tfoot>
                                             <tbody>
                                                <tr>
                                                   <td colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                      <paragraph>No Increase</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Toprule Botrule " valign="top">
                                                      <paragraph>90.7</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                                      <paragraph>390</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Toprule Botrule " valign="top">
                                                      <paragraph>91.1</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                                      <paragraph>418</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Toprule Botrule " valign="top">
                                                      <paragraph>91.2</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                                      <paragraph>341</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Toprule Botrule " valign="top">
                                                      <paragraph>91.1</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                                      <paragraph>357</paragraph>
                                                   </td>
                                                </tr>
                                                <tr>
                                                   <td styleCode="Lrule Botrule " valign="top">
                                                      <paragraph>Maximum Value</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Rrule Botrule " valign="top">
                                                      <paragraph>&gt;1× ULN<footnote ID="_RefID0EA6AG">ULN (Upper Limit of Normal) is defined as 200 U/L.</footnote>
                                                      </paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Botrule " valign="top">
                                                      <paragraph>9.3</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Rrule Botrule " valign="top">
                                                      <paragraph>40</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Botrule " valign="top">
                                                      <paragraph>8.9</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Rrule Botrule " valign="top">
                                                      <paragraph>41</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Botrule " valign="top">
                                                      <paragraph>8.8</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Rrule Botrule " valign="top">
                                                      <paragraph>33</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Botrule " valign="top">
                                                      <paragraph>8.9</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Rrule Botrule " valign="top">
                                                      <paragraph>35</paragraph>
                                                   </td>
                                                </tr>
                                                <tr>
                                                   <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                                                      <paragraph>&gt;2× ULN</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Botrule " valign="top">
                                                      <paragraph>4.9</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Rrule Botrule " valign="top">
                                                      <paragraph>21</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Botrule " valign="top">
                                                      <paragraph>4.8</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Rrule Botrule " valign="top">
                                                      <paragraph>22</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Botrule " valign="top">
                                                      <paragraph>3.7</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Rrule Botrule " valign="top">
                                                      <paragraph>14</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Botrule " valign="top">
                                                      <paragraph>3.1</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Rrule Botrule " valign="top">
                                                      <paragraph>12</paragraph>
                                                   </td>
                                                </tr>
                                                <tr>
                                                   <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                                                      <paragraph>&gt;4× ULN</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Botrule " valign="top">
                                                      <paragraph>1.4</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Rrule Botrule " valign="top">
                                                      <paragraph>6</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Botrule " valign="top">
                                                      <paragraph>1.5</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Rrule Botrule " valign="top">
                                                      <paragraph>7</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Botrule " valign="top">
                                                      <paragraph>1.1</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Rrule Botrule " valign="top">
                                                      <paragraph>4</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Botrule " valign="top">
                                                      <paragraph>1.0</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Rrule Botrule " valign="top">
                                                      <paragraph>4</paragraph>
                                                   </td>
                                                </tr>
                                                <tr>
                                                   <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                                                      <paragraph>&gt;5× ULN</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Botrule " valign="top">
                                                      <paragraph>1.4</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Rrule Botrule " valign="top">
                                                      <paragraph>6</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Botrule " valign="top">
                                                      <paragraph>0.4</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Rrule Botrule " valign="top">
                                                      <paragraph>2</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Botrule " valign="top">
                                                      <paragraph>1.1</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Rrule Botrule " valign="top">
                                                      <paragraph>4</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Botrule " valign="top">
                                                      <paragraph>0.0</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Rrule Botrule " valign="top">
                                                      <paragraph>0</paragraph>
                                                   </td>
                                                </tr>
                                                <tr>
                                                   <td align="center" colspan="2" styleCode="Rrule Botrule Lrule " valign="top">
                                                      <paragraph>&gt;10× ULN</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Botrule " valign="top">
                                                      <paragraph>0.5</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Rrule Botrule " valign="top">
                                                      <paragraph>2</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Botrule " valign="top">
                                                      <paragraph>0.2</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Rrule Botrule " valign="top">
                                                      <paragraph>1</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Botrule " valign="top">
                                                      <paragraph>0.2</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Rrule Botrule " valign="top">
                                                      <paragraph>1</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Botrule " valign="top">
                                                      <paragraph>0.0</paragraph>
                                                   </td>
                                                   <td align="center" styleCode="Rrule Botrule " valign="top">
                                                      <paragraph>0</paragraph>
                                                   </td>
                                                </tr>
                                             </tbody>
                                          </table>
                                       </text>
                                       <effectiveTime value="20250228"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section ID="ID_b1312cfc-7a0f-4d9e-a33e-a05b14be4a0b">
                                       <id root="7ecd7167-55d8-466b-b2df-487afbd51ae9"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">S. aureus Bacteremia/Endocarditis Trial in Adults</content>
                                          </paragraph>
                                          <paragraph>In the <content styleCode="italics">S. aureus</content> bacteremia/endocarditis trial in adult patients, at a dose of 6 mg/kg, 11/120 (9.2%) daptomycin for injection-treated patients, including two patients with baseline CPK levels &gt;500 U/L, had CPK elevations to levels &gt;500 U/L, compared with 1/116 (0.9%) comparator-treated patients. Of the 11 daptomycin for injection-treated patients, 4 had prior or concomitant treatment with an HMG-CoA reductase inhibitor. Three of these 11 daptomycin for injection-treated patients discontinued therapy due to CPK elevation, while the one comparator-treated patient did not discontinue therapy <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>].</content>
                                          </paragraph>
                                       </text>
                                       <effectiveTime value="20220818"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="2ee52625-7c6c-464e-bc85-81bc274c3c35"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Post-Marketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of daptomycin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Blood and lymphatic system disorders:</content> anemia, thrombocytopenia</paragraph>
                        <paragraph>
                           <content styleCode="italics">General and administration site conditions:</content> pyrexia</paragraph>
                        <paragraph>
                           <content styleCode="italics">Immune System Disorders:</content> anaphylaxis; hypersensitivity reactions, including angioedema, pruritus, hives, shortness of breath, difficulty swallowing, truncal erythema, and pulmonary eosinophilia <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml> and <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Infections and Infestations: Clostridioides difficile</content>–associated diarrhea <content styleCode="italics">[see <linkHtml href="#S5.8">Warnings and Precautions (5.8)</linkHtml>]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Laboratory Investigations:</content> platelet count decreased </paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal Disorders:</content> myoglobin increased; rhabdomyolysis (some reports involved patients treated concurrently with daptomycin and HMG-CoA reductase inhibitors) <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>, <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>, and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Respiratory, Thoracic, and Mediastinal Disorders:</content> cough, eosinophilic pneumonia, organizing pneumonia <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous System Disorders:</content> peripheral neuropathy <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and Subcutaneous Tissue Disorders:</content> serious skin reactions, including drug reaction with eosinophilia and systemic symptoms (DRESS), vesiculobullous rash (with or without mucous membrane involvement, including Stevens-Johnson syndrome [SJS] and toxic epidermal necrolysis [TEN]), and acute generalized exanthematous pustulosis <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal Disorders:</content> nausea, vomiting</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolic and Nutritional Disorders:</content> hyperkalemia</paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal and urinary disorders:</content> acute kidney injury, renal insufficiency, renal failure, and tubulointerstitial nephritis (TIN) <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Special Senses:</content> visual disturbances</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="e6c87486-7871-4476-94ec-913b0a52bab8"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20220818"/>
               <component>
                  <section ID="S7.1">
                     <id root="90f0cbce-d9c6-415e-94a4-88055bacaf2c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1	HMG-CoA Reductase Inhibitors</title>
                     <text>
                        <paragraph>In healthy adult subjects, concomitant administration of daptomycin and simvastatin had no effect on plasma trough concentrations of simvastatin, and there were no reports of skeletal myopathy <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>However, inhibitors of HMG-CoA reductase may cause myopathy, which is manifested as muscle pain or weakness associated with elevated levels of creatine phosphokinase (CPK). In the adult Phase 3 <content styleCode="italics">S. aureus</content> bacteremia/endocarditis trial, some patients who received prior or concomitant treatment with an HMG-CoA reductase inhibitor developed elevated CPK <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>].</content> Experience with the co-administration of HMG-CoA reductase inhibitors and daptomycin in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin for Injection.</paragraph>
                     </text>
                     <effectiveTime value="20220818"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.2">
                     <id root="df91950b-f416-42d7-bf89-f0b6dad5b181"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2	Drug-Laboratory Test Interactions</title>
                     <text>
                        <paragraph>Clinically relevant plasma concentrations of daptomycin have been observed to cause a significant concentration-dependent false prolongation of prothrombin time (PT) and elevation of International Normalized Ratio (INR) when certain recombinant thromboplastin reagents are utilized for the assay. The possibility of an erroneously elevated PT/INR result due to interaction with a recombinant thromboplastin reagent may be minimized by drawing specimens for PT or INR testing near the time of trough plasma concentrations of daptomycin. However, sufficient daptomycin concentrations may be present at trough to cause interaction.</paragraph>
                        <paragraph>If confronted with an abnormally high PT/INR result in a patient being treated with daptomycin, it is recommended that clinicians:</paragraph>
                        <list listType="ordered">
                           <item>
                              <caption>1.</caption>Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin for Injection dose (i.e., at trough concentration). If the PT/INR value obtained at trough remains substantially elevated above what would otherwise be expected, consider evaluating PT/INR utilizing an alternative method.</item>
                           <item>
                              <caption>2.</caption>Evaluate for other causes of abnormally elevated PT/INR results.</item>
                        </list>
                     </text>
                     <effectiveTime value="20220818"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="0ecfb33b-c0f3-467f-a22a-9fb5d04844db"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250228"/>
               <component>
                  <section ID="S8.1">
                     <id root="0ac4cc09-d1fa-4def-b155-6847f5ee921d"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20250228"/>
                     <component>
                        <section ID="ID_0b462aa9-c279-4168-8c1e-a22917f8858d">
                           <id root="6cac2158-c280-4365-a9e8-fa6af0e86d6c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Limited published data on use of daptomycin in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage. In animal reproduction studies performed in rats and rabbits daptomycin was administered intravenously during organogenesis at doses 2 and 4-times, respectively, the recommended 6 mg/kg human dose (on a body surface area basis). No evidence of adverse developmental outcomes was observed.</paragraph>
                              <paragraph>The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20220818"/>
                        </section>
                     </component>
                     <component>
                        <section ID="data">
                           <id root="67da6c91-55e4-41b0-81d2-4746f062cc07"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph ID="Data">
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250228"/>
                           <component>
                              <section ID="ID_80e2646f-4a7c-46f4-9bfd-8daa7edc11c2">
                                 <id root="27ae8d9b-cbee-4dda-acb9-a0a4f26b2e88"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>In pregnant rats, daptomycin was administered intravenously at doses of 5, 20, or 75 mg/kg/day during the gestation days 6 to 18. Maternal body weight gain was decreased at 75 mg/kg/day. No embryo/fetal effects were noted at the highest dose of 75 mg/kg/day, a dose approximately 2-fold higher than in humans at the recommended maximum dose of 6 mg/kg (based on body surface area).</paragraph>
                                    <paragraph>In pregnant rabbits, daptomycin was administered intravenously at doses of 5, 20, or 75 mg/kg/day during the gestation days 6 to 15. Maternal body weight gain and food consumption were decreased at 75 mg/kg/day. No embryo/fetal effects were noted at the highest dose of 75 mg/kg/day, a dose approximately 4-fold higher than in humans at the maximum recommended dose of 6mg/kg (based on body surface area).</paragraph>
                                    <paragraph>In a combined fertility and pre/postnatal development study, daptomycin was administered intravenously to female rats at doses of 2, 25, 75 mg/kg/day from 14 days pre-mating through lactation/postpartum day 20). No effects on pre/postnatal development were observed up to the highest dose of 75 mg/kg/day, a dose approximately 2-fold higher than the maximum recommended human dose of 6 mg/kg (based on body surface area)<sup>1</sup>.</paragraph>
                                 </text>
                                 <effectiveTime value="20220818"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="24b65919-6150-40db-9a25-d19ca5619600"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20250228"/>
                     <component>
                        <section ID="ID_0a711440-00b3-44b4-8ff0-4f51966f7c22">
                           <id root="2f6a1a81-403b-4cb8-9ecf-fa4292a1d25c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Limited published data report that daptomycin is present in human milk at infant doses of 0.1% of the maternal dose <content styleCode="italics">(see <linkHtml href="#Data">Data</linkHtml>)</content>
                                 <sup>2,3,4</sup>. There is no information on the effects of daptomycin on the breastfed infant or the effects of daptomycin on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Daptomycin for Injection and any potential adverse effects on the breastfed infant from Daptomycin for Injection or from the underlying maternal condition.</paragraph>
                           </text>
                           <effectiveTime value="20250228"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="f1202567-9abc-495b-ab6f-b252a42f43bc"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>This Daptomycin for Injection product is not approved for use in pediatric patients.</paragraph>
                        <paragraph>Safety and effectiveness of daptomycin for injection in pediatric patients below the age of one year have not been established. Avoid use of Daptomycin for Injection in pediatric patients younger than one year of age due to the risk of potential effects on muscular, neuromuscular, and/or nervous systems (either peripheral and/or central) observed in neonatal dogs <content styleCode="italics">[see <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml> and <linkHtml href="#S13.2">Nonclinical Toxicology (13.2)</linkHtml>]</content>.</paragraph>
                        <paragraph>Daptomycin for Injection is not indicated in pediatric patients with renal impairment because dosage has not been established in these patients.</paragraph>
                     </text>
                     <effectiveTime value="20220818"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="120391a6-4579-4faf-a3be-ebe1fe366942"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Of the 534 adult patients treated with daptomycin for injection in Phase 3 controlled clinical trials of complicated skin and skin structure infections (cSSSI), 27% were 65 years of age or older and 12% were 75 years of age or older. Of the 120 adult patients treated with daptomycin for injection in the Phase 3 controlled clinical trial of <content styleCode="italics">S. aureus</content> bacteremia/endocarditis, 25% were 65 years of age or older and 16% were 75 years of age or older. In Phase 3 adult clinical trials of cSSSI and <content styleCode="italics">S. aureus</content> bacteremia/endocarditis, clinical success rates were lower in patients ≥65 years of age than in patients &lt;65 years of age. In addition, treatment-emergent adverse events were more common in patients ≥65 years of age than in patients &lt;65 years of age.</paragraph>
                        <paragraph>The exposure of daptomycin was higher in healthy elderly subjects than in healthy young adult subjects. However, no adjustment of Daptomycin for Injection dosage is warranted for elderly patients with creatinine clearance (CL<sub>CR</sub>) ≥30 mL/min <content styleCode="italics">[see <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml> and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220818"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="6ef57072-90a9-4474-8b9a-d914c8d36dfb"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.6	Patients with Renal Impairment</title>
                     <text>
                        <paragraph>Daptomycin is eliminated primarily by the kidneys; therefore, a modification of daptomycin dosage interval is recommended for adult patients with CL<sub>CR</sub> &lt;30 mL/min, including patients receiving hemodialysis or continuous ambulatory peritoneal dialysis (CAPD). In adult patients with renal impairment, both renal function and creatine phosphokinase (CPK) should be monitored more frequently than once weekly <content styleCode="italics">[see <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>, <linkHtml href="#S5.2">Warnings and Precautions (5.2</linkHtml>, <linkHtml href="#S5.10">5.10)</linkHtml>, and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>The dosage regimen for Daptomycin for Injection in pediatric patients with renal impairment has not been established.</paragraph>
                     </text>
                     <effectiveTime value="20220818"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="8859adde-032c-4cb6-805c-b88c20d4f11b"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>In the event of overdosage, supportive care is advised with maintenance of glomerular filtration. Daptomycin is cleared slowly from the body by hemodialysis (approximately 15% of the administered dose is removed over 4 hours) and by peritoneal dialysis (approximately 11% of the administered dose is removed over 48 hours). The use of high-flux dialysis membranes during 4 hours of hemodialysis may increase the percentage of dose removed compared with that removed by low-flux membranes.</paragraph>
               </text>
               <effectiveTime value="20220818"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="b3997799-9e71-46a9-85ee-d80a916cba0c"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Daptomycin for Injection contains daptomycin, a cyclic lipopeptide antibacterial agent derived from the fermentation of <content styleCode="italics">Streptomyces roseosporus</content>. The chemical name is <content styleCode="italics">N</content>-decanoyl-L-tryptophyl-D-asparaginyl-L-aspartyl-L‑threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-<content styleCode="italics">threo</content>-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine ε1‑ lactone. The chemical structure is:</paragraph>
                  <renderMultiMedia ID="id1749" referencedObject="MM1"/>
                  <paragraph>The empirical formula is C<sub>72</sub>H<sub>101</sub>N<sub>17</sub>O<sub>26</sub>; the molecular weight is 1620.67. Daptomycin for Injection is supplied in a single-dose vial as a sterile, preservative-free, pale yellow to light brown, lyophilized cake containing 350 mg or 500 mg of daptomycin for intravenous (IV) use following reconstitution with 0.9% sodium chloride injection <content styleCode="italics">[see <linkHtml href="#S2.5">Dosage and Administration (2.5)</linkHtml>]</content>. Daptomycin for Injection 350 mg per vial, contains 350 mg daptomycin and 53.8 mg citric acid. Sodium hydroxide is used to adjust the pH. Daptomycin for Injection 500 mg per vial contains 500 mg daptomycin, and 76.8 mg citric acid. Sodium hydroxide is used to adjust the pH. Freshly reconstituted solutions of Daptomycin for Injection range in color from light yellow to light brown.</paragraph>
               </text>
               <effectiveTime value="20220818"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="daptomycin-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="70b8d20e-160e-44dc-aab9-12fd19de4dc0"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250228"/>
               <component>
                  <section ID="S12.1">
                     <id root="30d5ca69-21e7-4cbc-89c4-4d6a3a6dacbd"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Daptomycin is an antibacterial drug <content styleCode="italics">[see <linkHtml href="#S12.4">Clinical Pharmacology (12.4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220818"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="5d8addb8-02a4-44a8-9081-69d3977e0faf"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Based on animal models of infection, the antimicrobial activity of daptomycin appears to correlate with the AUC/MIC (area under the concentration-time curve/minimum inhibitory concentration) ratio for certain pathogens, including <content styleCode="italics">S. aureus</content>. The principal pharmacokinetic/pharmacodynamic parameter best associated with clinical and microbiological cure has not been elucidated in clinical trials with daptomycin for injection.</paragraph>
                     </text>
                     <effectiveTime value="20220818"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="b14582f2-82ad-4e15-8f10-25df410ffd89"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <effectiveTime value="20250228"/>
                     <component>
                        <section ID="ID_7ffb6375-6cde-4f77-95cd-eb2e2205b39c">
                           <id root="46a93396-b14d-457c-9de0-02b0561c9742"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Daptomycin for Injection Administered over a 30-Minute Period in Adults</content>
                              </paragraph>
                              <paragraph>The mean and standard deviation (SD) pharmacokinetic parameters of daptomycin at steady-state following intravenous (IV) administration of daptomycin for injection over a 30-minute period at 4 to 12 mg/kg every 24h to healthy young adults are summarized in Table 7.</paragraph>
                              <table ID="_Reftable7" width="85%">
                                 <caption>Table 7: Mean (SD) Daptomycin Pharmacokinetic Parameters in Healthy Adult Volunteers at Steady-State</caption>
                                 <col width="15%"/>
                                 <col width="17%"/>
                                 <col width="16%"/>
                                 <col width="17%"/>
                                 <col width="17%"/>
                                 <col width="17%"/>
                                 <thead>
                                    <tr>
                                       <th align="left" rowspan="2" styleCode="Rrule Lrule Toprule " valign="top">
                                          <content styleCode="bold">Dose</content>
                                          <footnote ID="_Reffoot7a">Daptomycin for injection was administered by IV infusion over a 30-minute period.</footnote>
                                          <footnote ID="_Reffoot7b">Doses of daptomycin for injection in excess of 6 mg/kg have not been approved.</footnote>
                                          <content styleCode="bold"> (mg/kg)</content>
                                       </th>
                                       <th align="center" colspan="5" styleCode="Rrule Botrule Toprule " valign="top">
                                          <content styleCode="bold">Pharmacokinetic Parameters</content>
                                          <footnote ID="_Reffoot7c">AUC<sub>0–24</sub>, area under the concentration-time curve from 0 to 24 hours; t<sub>1/2</sub>, elimination half-life; V<sub>ss</sub>, volume of distribution at steady-state; CL<sub>T</sub>, total plasma clearance; C<sub>max</sub>, maximum plasma concentration.</footnote>
                                       </th>
                                    </tr>
                                    <tr>
                                       <th align="center" styleCode="Rrule Botrule " valign="top">
                                          <content styleCode="bold">AUC<sub>0–24</sub>
                                          </content>
                                          <br/>
                                          <content styleCode="bold">(mcg∙h/mL)</content>
                                       </th>
                                       <th align="center" styleCode="Rrule Botrule " valign="top">
                                          <content styleCode="bold">t<sub>1/2</sub> (h)</content>
                                       </th>
                                       <th align="center" styleCode="Rrule Botrule " valign="top">
                                          <content styleCode="bold">V<sub>ss</sub> (L/kg)</content>
                                       </th>
                                       <th align="center" styleCode="Rrule Botrule " valign="top">
                                          <content styleCode="bold">CL<sub>T</sub>
                                          </content>
                                          <br/>
                                          <content styleCode="bold">(mL/h/kg)</content>
                                       </th>
                                       <th align="center" styleCode="Rrule Botrule " valign="top">
                                          <content styleCode="bold">C<sub>max</sub>
                                          </content>
                                          <br/>
                                          <content styleCode="bold">(mcg/mL)</content>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>4 (N=6)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                          <paragraph>494 (75)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                          <paragraph>8.1 (1.0)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                          <paragraph>0.096 (0.009)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                          <paragraph>8.3 (1.3)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                          <paragraph>57.8 (3.0)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>6 (N=6)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>632 (78)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>7.9 (1.0)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>0.101 (0.007)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>9.1 (1.5)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>93.9 (6.0)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>8 (N=6)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>858 (213)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>8.3 (2.2)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>0.101 (0.013)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>9.0 (3.0)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>123.3 (16.0)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>10 (N=9)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>1039 (178)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>7.9 (0.6)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>0.098 (0.017)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>8.8 (2.2)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>141.1 (24.0)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Botrule Lrule " valign="top">
                                          <paragraph>12 (N=9)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>1277 (253)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>7.7 (1.1)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>0.097 (0.018)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>9.0 (2.8)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>183.7 (25.0)</paragraph>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Daptomycin pharmacokinetics were generally linear and time-independent at Daptomycin for Injection doses of 4 to 12 mg/kg every 24h administered by IV infusion over a 30-minute period for up to 14 days. Steady-state trough concentrations were achieved by the third daily dose. The mean (SD) steady-state trough concentrations attained following the administration of 4, 6, 8, 10, and 12 mg/kg every 24h were 5.9 (1.6), 6.7 (1.6), 10.3 (5.5), 12.9 (2.9), and 13.7 (5.2) mcg/mL, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20220818"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_c6cedf43-7d79-4e2d-81ea-c4162db8961b">
                           <id root="86b96e20-c5c2-4e9d-9742-f1fbb4464842"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Daptomycin for Injection Administered over a 2-Minute Period in Adults</content>
                              </paragraph>
                              <paragraph>Following IV administration of daptomycin for injection over a 2-minute period to healthy adult volunteers at doses of 4 mg/kg (N=8) and 6 mg/kg (N=12), the mean (SD) steady-state systemic exposure (AUC) values were 475 (71) and 701 (82) mcg∙h/mL, respectively. Values for maximum plasma concentration (C<sub>max</sub>) at the end of the 2-minute period could not be determined adequately in this study. However, using pharmacokinetic parameters from 14 healthy adult volunteers who received a single-dose of daptomycin for injection 6 mg/kg IV administered over a 30-minute period in a separate study, steady-state C<sub>max</sub> values were simulated for daptomycin for injection 4 and 6 mg/kg IV administered over a 2-minute period. The simulated mean (SD) steady-state C<sub>max</sub> values were 77.7 (8.1) and 116.6 (12.2) mcg/mL, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20220818"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_771acf41-44d0-4bf2-892b-affdf8a00f9d">
                           <id root="9b0929e8-c608-4d61-ba29-6b008fc71692"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>Daptomycin is reversibly bound to human plasma proteins, primarily to serum albumin, in a concentration-independent manner. The overall mean binding ranges from 90 to 93%.</paragraph>
                              <paragraph>In clinical studies, mean serum protein binding in adult subjects with creatinine clearance (CL<sub>CR</sub>) ≥30 mL/min was comparable to that observed in healthy adult subjects with normal renal function. However, there was a trend toward decreasing serum protein binding among subjects with CL<sub>CR</sub> &lt;30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%). The protein binding of daptomycin in adult subjects with moderate hepatic impairment (Child-Pugh Class B) was similar to that in healthy adult subjects.</paragraph>
                              <paragraph>The volume of distribution at steady-state (Vss) of daptomycin in healthy adult subjects was approximately 0.1 L/kg and was independent of dose.</paragraph>
                           </text>
                           <effectiveTime value="20220818"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_e9064e1e-e543-48cc-8bf7-e2d8be285900">
                           <id root="2b0bbfcd-2368-47fb-a63c-ad39503760f9"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Metabolism</content>
                              </paragraph>
                              <paragraph>In <content styleCode="italics">in vitro</content> studies, daptomycin was not metabolized by human liver microsomes.</paragraph>
                              <paragraph>In 5 healthy adults after infusion of radiolabeled <sup>14</sup>C-daptomycin, the plasma total radioactivity was similar to the concentration determined by microbiological assay. Inactive metabolites were detected in urine, as determined by the difference between total radioactive concentrations and microbiologically active concentrations. In a separate study, no metabolites were observed in plasma on Day 1 following the administration of daptomycin for injection at 6 mg/kg to adult subjects. Minor amounts of three oxidative metabolites and one unidentified compound were detected in urine. The site of metabolism has not been identified.</paragraph>
                           </text>
                           <effectiveTime value="20220818"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_1662601c-b70a-4a7f-87bc-e1bcdd33b3e0">
                           <id root="9c897ef9-449c-46d9-8441-90c3bc60e949"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Excretion</content>
                              </paragraph>
                              <paragraph>Daptomycin is excreted primarily by the kidneys. In a mass balance study of 5 healthy adult subjects using radiolabeled daptomycin, approximately 78% of the administered dose was recovered from urine based on total radioactivity (approximately 52% of the dose based on microbiologically active concentrations), and 5.7% of the administered dose was recovered from feces (collected for up to 9 days) based on total radioactivity.</paragraph>
                           </text>
                           <effectiveTime value="20220818"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_c4369a59-9159-479f-8b53-0387665e6a85">
                           <id root="8fd15e9f-b92b-48a2-8c4e-d45e9ae4d988"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250228"/>
                           <component>
                              <section ID="ID_42b8d76f-d6ba-478b-b0a1-805bc9060583">
                                 <id root="3cd9c83d-4f56-4ced-a5cb-38e76cb6d934"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Renal Impairment</content>
                                    </paragraph>
                                    <paragraph>Population-derived pharmacokinetic parameters were determined for infected adult patients (complicated skin and skin structure infections [cSSSI] and <content styleCode="italics">S. aureus</content> bacteremia) and noninfected adult subjects with various degrees of renal function (Table 8). Total plasma clearance (CL<sub>T</sub>), elimination half-life (t<sub>1/2</sub>), and volume of distribution at steady-state (V<sub>ss</sub>) in patients with cSSSI were similar to those in patients with <content styleCode="italics">S. aureus</content> bacteremia. Following administration of daptomycin for injection 4 mg/kg every 24h by IV infusion over a 30-minute period, the mean CL<sub>T</sub> was 9%, 22%, and 46% lower among subjects and patients with mild (CL<sub>CR</sub> 50–80 mL/min), moderate (CL<sub>CR</sub> 30–&lt;50 mL/min), and severe (CL<sub>CR</sub> &lt;30 mL/min) renal impairment, respectively, than in those with normal renal function (CL<sub>CR</sub> &gt;80 mL/min). The mean steady-state systemic exposure (AUC), t<sub>1/2</sub>, and V<sub>ss</sub> increased with decreasing renal function, although the mean AUC for patients with CL<sub>CR</sub> 30–80 mL/min was not markedly different from the mean AUC for patients with normal renal function. The mean AUC for patients with CL<sub>CR</sub> &lt;30 mL/min and for patients on dialysis (CAPD and hemodialysis dosed post-dialysis) was approximately 2 and 3 times higher, respectively, than for patients with normal renal function. The mean C<sub>max</sub> ranged from 60 to 70 mcg/mL in patients with CL<sub>CR</sub> ≥30 mL/min, while the mean C<sub>max</sub> for patients with CL<sub>CR</sub> &lt;30 mL/min ranged from 41 to 58 mcg/mL. After administration of daptomycin for injection 6 mg/kg every 24h by IV infusion over a 30-minute period, the mean C<sub>max</sub> ranged from 80 to 114 mcg/mL in patients with mild to moderate renal impairment and was similar to that of patients with normal renal function.</paragraph>
                                    <table ID="_Reftable8" width="85%">
                                       <caption>Table 8: Mean (SD) Daptomycin Population Pharmacokinetic Parameters Following Infusion of Daptomycin for Injection 4 mg/kg or 6 mg/kg to Infected Adult Patients and Noninfected Adult Subjects with Various Degrees of Renal Function</caption>
                                       <col width="16%"/>
                                       <col width="16%"/>
                                       <col width="13%"/>
                                       <col width="13%"/>
                                       <col width="14%"/>
                                       <col width="14%"/>
                                       <col width="13%"/>
                                       <thead>
                                          <tr>
                                             <th align="left" rowspan="2" styleCode="Rrule Lrule Toprule " valign="middle">
                                                <content styleCode="bold">Renal Function</content>
                                             </th>
                                             <th align="center" colspan="6" styleCode="Rrule Botrule Toprule " valign="top">
                                                <content styleCode="bold">Pharmacokinetic Parameters</content>
                                                <footnote ID="_RefID0EU5BG">CL<sub>CR</sub>, creatinine clearance estimated using the Cockcroft-Gault equation with actual body weight; CAPD, continuous ambulatory peritoneal dialysis; AUC<content styleCode="bold">
                                                      <sub>0–∞</sub>
                                                   </content>, area under the concentration-time curve extrapolated to infinity; AUC<sub>SS</sub>, area under the concentration-time curve calculated over the 24-hour dosing interval at steady-state; C<sub>min, SS</sub>, trough concentration at steady-state; NA, not applicable.</footnote>
                                             </th>
                                          </tr>
                                          <tr>
                                             <th align="center" styleCode="Rrule Botrule " valign="top">
                                                <content styleCode="bold">t<sub>1/2</sub>
                                                </content>
                                                <footnote ID="_Reffoot8b">Parameters obtained following a single dose from patients with complicated skin and skin structure infections and healthy subjects.</footnote>
                                                <content styleCode="bold"> (h)</content>
                                                <br/>
                                                <content styleCode="bold">4 mg/kg</content>
                                             </th>
                                             <th align="center" styleCode="Rrule Botrule " valign="top">
                                                <content styleCode="bold">Vss</content>
                                                <footnoteRef IDREF="_Reffoot8b"/>
                                                <content styleCode="bold"> (L/kg)</content>
                                                <br/>
                                                <content styleCode="bold">4 mg/kg</content>
                                             </th>
                                             <th align="center" styleCode="Rrule Botrule " valign="top">
                                                <content styleCode="bold">CL<sub>T</sub>
                                                </content>
                                                <footnoteRef IDREF="_Reffoot8b"/>
                                                <br/>
                                                <content styleCode="bold">(mL/h/kg) </content>
                                                <br/>
                                                <content styleCode="bold">4 mg/kg</content>
                                             </th>
                                             <th align="center" styleCode="Rrule Botrule " valign="top">
                                                <content styleCode="bold">AUC<sub>0–∞</sub>
                                                </content>
                                                <br/>
                                                <content styleCode="bold">(mcg∙h/mL) </content>
                                                <br/>
                                                <content styleCode="bold">4 mg/kg</content>
                                             </th>
                                             <th align="center" styleCode="Rrule Botrule " valign="top">
                                                <content styleCode="bold">AUC<sub>ss</sub>
                                                </content>
                                                <footnote ID="_Reffoot8c">Parameters obtained at steady-state from patients with <content styleCode="italics">S. aureus</content> bacteremia.</footnote>
                                                <br/>
                                                <content styleCode="bold">(mcg∙h/mL) </content>
                                                <br/>
                                                <content styleCode="bold">6 mg/kg</content>
                                             </th>
                                             <th align="center" styleCode="Rrule Botrule " valign="top">
                                                <content styleCode="bold">C<sub>min, SS</sub>
                                                </content>
                                                <footnoteRef IDREF="_Reffoot8c"/>
                                                <br/>
                                                <content styleCode="bold">(mcg/mL) </content>
                                                <br/>
                                                <content styleCode="bold">6 mg/kg</content>
                                             </th>
                                          </tr>
                                       </thead>
                                       <tfoot>
                                          <tr>
                                             <td align="left" colspan="7" valign="top">Note: Daptomycin for injection was administered over a 30-minute period.</td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>Normal<br/>(CL<sub>CR</sub> &gt;80 mL/min)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                                <paragraph>9.39 (4.74)<br/>N=165</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                                <paragraph>0.13 (0.05) <br/>N=165</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                                <paragraph>10.9 (4.0) <br/>N=165</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                                <paragraph>417 (155) <br/>N=165</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                                <paragraph>545 (296) <br/>N=62</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                                <paragraph>6.9 (3.5) <br/>N=61</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Mild Renal Impairment (CL<sub>CR</sub> 50–80 mL/min)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>10.75 (8.36) <br/>N=64</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>0.12 (0.05)<br/> N=64</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>9.9 (4.0) <br/>N=64</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>466 (177)<br/>N=64</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>637 (215) <br/>N=29</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>12.4 (5.6)<br/> N=29</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Moderate Renal Impairment<br/>(CL<sub>CR</sub> 30–&lt;50 mL/min)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>14.70 (10.50)<br/>N=24</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>0.15 (0.06) <br/>N=24</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>8.5 (3.4) <br/>N=24</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>560 (258) <br/>N=24</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>868 (349)<br/>N=15</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>19.0 (9.0)<br/>N=14</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Severe Renal Impairment<br/>(CL<sub>CR</sub> &lt;30 mL/min)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>27.83(14.85) <br/>N=8</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>0.20 (0.15) <br/>N=8</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>5.9 (3.9)<br/>N=8</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>925 (467) <br/>N=8</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>1050 (892)<br/>N=2</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>24.4 (21.4)<br/>N=2</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Hemodialysis</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>30.51 (6.51) <br/>N=16</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>0.16 (0.04) <br/>N=16</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>3.9 (2.1) <br/>N=16</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>1193 (399) <br/>N=16</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>NA</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>NA</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Botrule Lrule " valign="top">
                                                <paragraph>CAPD</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>27.56 (4.53) <br/>N=5</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>0.11 (0.02) <br/>N=5</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>2.9 (0.4)<br/>N=5</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>1409 (238) <br/>N=5</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>NA</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule " valign="top">
                                                <paragraph>NA</paragraph>
                                             </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <paragraph>Because renal excretion is the primary route of elimination, adjustment of daptomycin for injection dosage interval is necessary in adult patients with severe renal impairment (CL<sub>CR</sub> &lt;30 mL/min) <content styleCode="italics">[see <linkHtml href="#S2.6">Dosage and Administration (2.6)</linkHtml>].</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250228"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_c199fa4b-57aa-415e-aba7-5ea7e3c20d40">
                                 <id root="64add79e-3df7-4728-a32f-10db1645782e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Hepatic Impairment</content>
                                    </paragraph>
                                    <paragraph>The pharmacokinetics of daptomycin were evaluated in 10 adult subjects with moderate hepatic impairment (Child-Pugh Class B) and compared with those in healthy adult volunteers (N=9) matched for gender, age, and weight. The pharmacokinetics of daptomycin were not altered in subjects with moderate hepatic impairment. No dosage adjustment is warranted when daptomycin for injection is administered to patients with mild to moderate hepatic impairment. The pharmacokinetics of daptomycin in patients with severe hepatic impairment (Child-Pugh Class C) have not been evaluated.</paragraph>
                                 </text>
                                 <effectiveTime value="20220818"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_19f57ccb-c94d-450e-bfdb-6ca3555a40e0">
                                 <id root="2469394f-fd69-4d5e-8e94-7cec65d7ffc7"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Gender</content>
                                    </paragraph>
                                    <paragraph>No clinically significant gender-related differences in daptomycin pharmacokinetics have been observed. No dosage adjustment is warranted based on gender when daptomycin for injection is administered.</paragraph>
                                 </text>
                                 <effectiveTime value="20220818"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_b28372da-7d3c-4680-8407-ecbc1cbc4f14">
                                 <id root="5a8d8ec1-0af3-424e-af02-acfd5a1f64c6"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Geriatric Patients</content>
                                    </paragraph>
                                    <paragraph>The pharmacokinetics of daptomycin were evaluated in 12 healthy elderly subjects (≥75 years of age) and 11 healthy young adult controls (18 to 30 years of age). Following administration of a single 4 mg/kg dose of daptomycin for injection by IV infusion over a 30-minute period, the mean total clearance of daptomycin was approximately 35% lower and the mean AUC<content styleCode="bold">
                                          <sub>0–∞</sub>
                                       </content> was approximately 58% higher in elderly subjects than in healthy young adult subjects. There were no differences in C<sub>max</sub>
                                       <content styleCode="italics"> [see <linkHtml href="#S8.5">Use in Specific Populations (8.5)</linkHtml>].</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20220818"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_dda70a18-4054-4cc2-83cc-9df849bfa67a">
                                 <id root="9a396dc8-fe88-4b54-a58c-dba2b548ac4e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Obese Patients</content>
                                    </paragraph>
                                    <paragraph>The pharmacokinetics of daptomycin were evaluated in 6 moderately obese (Body Mass Index [BMI] 25 to 39.9 kg/m<sup>2</sup>) and 6 extremely obese (BMI ≥40 kg/m<sup>2</sup>) adult subjects and controls matched for age, gender, and renal function. Following administration of daptomycin for injection by IV infusion over a 30-minute period as a single 4 mg/kg dose based on total body weight, the total plasma clearance of daptomycin normalized to total body weight was approximately 15% lower in moderately obese subjects and 23% lower in extremely obese subjects than in nonobese controls. The AUC<content styleCode="bold">
                                          <sub>0–∞</sub>
                                       </content> of daptomycin was approximately 30% higher in moderately obese subjects and 31% higher in extremely obese subjects than in nonobese controls. The differences were most likely due to differences in the renal clearance of daptomycin. No adjustment of Daptomycin for Injection dosage is warranted in obese patients.</paragraph>
                                 </text>
                                 <effectiveTime value="20220818"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_72dd027d-8656-4f43-85f2-5ce7d3d8e54e">
                           <id root="4211ed98-f1e9-4970-9e4f-44ab05dde1e4"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interaction Studies</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20220818"/>
                           <component>
                              <section ID="ID_bff367be-ec45-4934-86b9-6744b2e762c7">
                                 <id root="2780a08f-476c-45f6-ae96-3e2b8e3e6ed4"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">In Vitro Studies</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">In vitro</content> studies with human hepatocytes indicate that daptomycin does not inhibit or induce the activities of the following human cytochrome P450 isoforms: 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4. It is unlikely that daptomycin will inhibit or induce the metabolism of drugs metabolized by the P450 system.</paragraph>
                                 </text>
                                 <effectiveTime value="20220818"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_78badf1f-0d51-451c-9637-4771c20257e1">
                                 <id root="3133e34b-d8e5-4006-a6ae-d246af57e843"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Aztreonam</content>
                                    </paragraph>
                                    <paragraph>In a study in which 15 healthy adult subjects received a single dose of daptomycin for injection 6 mg/kg IV and a combination dose of daptomycin 6 mg/kg IV and aztreonam 1 g IV, administered over a 30-minute period, the C<sub>max</sub> and AUC<sub>0–∞</sub> of daptomycin were not significantly altered by aztreonam.</paragraph>
                                 </text>
                                 <effectiveTime value="20220818"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_f7fac54c-a104-4f09-900c-36f79c7857fa">
                                 <id root="66c7f828-ab2b-430f-881d-68288840b48c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Tobramycin</content>
                                    </paragraph>
                                    <paragraph>In a study in which 6 healthy adult males received a single dose of daptomycin for injection 2 mg/kg IV, tobramycin 1 mg/kg IV, and both in combination, administered over a 30-minute period, the mean C<sub>max</sub> and AUC<sub>0–∞</sub> of daptomycin were 12.7% and 8.7% higher, respectively, when daptomycin for injection was co-administered with tobramycin. The mean C<sub>max</sub> and AUC<sub>0–∞</sub> of tobramycin were 10.7% and 6.6% lower, respectively, when tobramycin was co-administered with daptomycin for injection. These differences were not statistically significant. The interaction between daptomycin and tobramycin with a clinical dose of daptomycin for injection is unknown.</paragraph>
                                 </text>
                                 <effectiveTime value="20220818"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_404baa65-7161-4d71-bbb4-931b291e91a0">
                                 <id root="9819582b-fd61-4492-bac9-236316d7783f"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Warfarin</content>
                                    </paragraph>
                                    <paragraph>In 16 healthy adult subjects, administration of daptomycin for injection 6 mg/kg every 24h by IV infusion over a 30-minute period for 5 days, with co-administration of a single oral dose of warfarin (25 mg) on the 5<sup>th</sup> day, had no significant effect on the pharmacokinetics of either drug and did not significantly alter the INR (International Normalized Ratio).</paragraph>
                                 </text>
                                 <effectiveTime value="20220818"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_c70ce169-7b84-49ca-b1fa-9f4167f4fc41">
                                 <id root="1595bd04-8eea-4514-af89-dd2a83426886"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Simvastatin</content>
                                    </paragraph>
                                    <paragraph>In 20 healthy adult subjects on a stable daily dose of simvastatin 40 mg, administration of daptomycin for injection 4 mg/kg every 24h by IV infusion over a 30-minute period for 14 days (N=10) had no effect on plasma trough concentrations of simvastatin and was not associated with a higher incidence of adverse events, including skeletal myopathy, than in subjects receiving placebo once daily (N=10) <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml> and <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>].</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20220818"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_832695ad-98a7-45d3-955e-6d597d6ddefe">
                                 <id root="5624c8ec-969b-473c-a02b-ed5d3201bf83"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Probenecid</content>
                                    </paragraph>
                                    <paragraph>Concomitant administration of probenecid (500 mg 4 times daily) and a single dose of daptomycin for injection 4 mg/kg by IV infusion over a 30-minute period in adults did not significantly alter the C<sub>max</sub> or AUC<sub>0–∞</sub> of daptomycin.</paragraph>
                                 </text>
                                 <effectiveTime value="20220818"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.4">
                     <id root="1d43c634-d9eb-4d71-b9f5-931106739314"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>12.4 Microbiology</title>
                     <text>
                        <paragraph>Daptomycin belongs to the cyclic lipopeptide class of antibacterials. Daptomycin has clinical utility in the treatment of infections caused by aerobic, Gram-positive bacteria. The <content styleCode="italics">in vitro</content> spectrum of activity of daptomycin encompasses most clinically relevant Gram-positive pathogenic bacteria.</paragraph>
                        <paragraph>Daptomycin exhibits rapid, concentration-dependent bactericidal activity against Gram-positive bacteria <content styleCode="italics">in vitro</content>. This has been demonstrated both by time-kill curves and by MBC/MIC (minimum bactericidal concentration/minimum inhibitory concentration) ratios using broth dilution methodology. Daptomycin maintained bactericidal activity <content styleCode="italics">in vitro</content> against stationary phase <content styleCode="italics">S. aureus</content> in simulated endocardial vegetations. The clinical significance of this is not known.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                     <component>
                        <section ID="ID_5231129e-a68d-4538-aaa3-5a503ee4dcd6">
                           <id root="11de8091-d246-4b07-af5c-b29c40e32248"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mechanism of Action</content>
                              </paragraph>
                              <paragraph>Daptomycin binds to bacterial cell membranes and causes a rapid depolarization of membrane potential. This loss of membrane potential causes inhibition of DNA, RNA, and protein synthesis, which results in bacterial cell death.</paragraph>
                           </text>
                           <effectiveTime value="20220818"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_088359bb-927f-405a-b92e-6c8eb3060602">
                           <id root="06c3f454-44b1-4da3-895a-2943ed3cc87c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Resistance</content>
                              </paragraph>
                              <paragraph>The mechanism(s) of daptomycin resistance is not fully understood. Currently, there are no known transferable elements that confer resistance to daptomycin.</paragraph>
                           </text>
                           <effectiveTime value="20220818"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_436c05da-efa4-471a-8c05-aecd50fa3125">
                           <id root="723fee13-57db-4cb5-b487-fe35df4a5d9d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Interactions with Other Antibacterials</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">In vitro</content> studies have investigated daptomycin interactions with other antibacterials. Antagonism, as determined by kill curve studies, has not been observed. <content styleCode="italics">In vitro</content> synergistic interactions of daptomycin with aminoglycosides, β-lactam antibacterials, and rifampin have been shown against some isolates of staphylococci (including some methicillin-resistant isolates) and enterococci (including some vancomycin-resistant isolates).</paragraph>
                           </text>
                           <effectiveTime value="20220818"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_80ae1d81-8e02-4509-8628-316a4e56cd15">
                           <id root="0bc94686-691b-4f8a-936d-e33ae1914ede"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Complicated Skin and Skin Structure Infection (cSSSI) Trials in Adults</content>
                              </paragraph>
                              <paragraph>The emergence of daptomycin non-susceptible isolates occurred in 2 infected patients across the set of Phase 2 and pivotal Phase 3 clinical trials of cSSSI in adult patients. In one case, a non-susceptible <content styleCode="italics">S. aureus</content> was isolated from a patient in a Phase 2 trial who received daptomycin for injection at less than the protocol-specified dose for the initial 5 days of therapy. In the second case, a non-susceptible <content styleCode="italics">Enterococcus faecalis</content> was isolated from a patient with an infected chronic decubitus ulcer who was enrolled in a salvage trial.</paragraph>
                           </text>
                           <effectiveTime value="20220818"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_dfbd72ab-d799-4e3e-99a6-4ee344369c45">
                           <id root="cf2ef7ea-62ad-4386-8260-4c74bb3c129f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">
                                    <content styleCode="italics">S. aureus</content> Bacteremia/Endocarditis and Other Post-Approval Trials in Adults</content>
                              </paragraph>
                              <paragraph>In subsequent clinical trials in adult patients, non-susceptible isolates were recovered. <content styleCode="italics">S. aureus</content> was isolated from a patient in a compassionate-use trial and from 7 patients in the <content styleCode="italics">S. aureus</content> bacteremia/endocarditis trial <content styleCode="italics">[see <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>].</content> An <content styleCode="italics">E. faecium</content> was isolated from a patient in a vancomycin-resistant enterococci trial.</paragraph>
                           </text>
                           <effectiveTime value="20220818"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_194996d6-541c-4300-9415-dabcecdc0c10">
                           <id root="abc8b285-5ad2-4ae8-b48c-18d17cff27a3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Antimicrobial Activity</content>
                              </paragraph>
                              <paragraph>Daptomycin has been shown to be active against most isolates of the following microorganisms <content styleCode="underline">both <content styleCode="italics">in vitro</content> and in clinical infections</content>
                                 <content styleCode="italics"> [see <linkHtml href="#S1">Indications and Usage (1)</linkHtml>]</content>.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Gram-Positive Bacteria</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Enterococcus faecalis</content> (vancomycin-susceptible isolates only) <br/>
                                 <content styleCode="italics">Staphylococcus aureus</content> (including methicillin-resistant isolates) <br/>
                                 <content styleCode="italics">Streptococcus agalactiae</content>
                                 <br/>
                                 <content styleCode="italics">Streptococcus dysgalactiae</content> subsp. <content styleCode="italics">equisimilis</content>
                                 <br/>
                                 <content styleCode="italics">Streptococcus pyogenes</content>
                              </paragraph>
                              <paragraph>The following <content styleCode="italics">in vitro</content> data are available, but their clinical significance is unknown. At least 90 percent of the following bacteria exhibit an <content styleCode="italics">in vitro</content> minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for daptomycin against isolates of similar genus or organism group. However, the efficacy of daptomycin in treating clinical infections caused by these bacteria has not been established in adequate and well-controlled clinical trials.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Gram-Positive Bacteria</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Corynebacterium jeikeium</content>
                                 <br/>
                                 <content styleCode="italics">Enterococcus faecalis</content> (vancomycin-resistant isolates) <br/>
                                 <content styleCode="italics">Enterococcus faecium</content> (including vancomycin-resistant isolates) <br/>
                                 <content styleCode="italics">Staphylococcus epidermidis</content> (including methicillin-resistant isolates) <content styleCode="italics">Staphylococcus haemolyticus</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20220818"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_059a8459-4353-42ce-b703-8a9b7017dc06">
                           <id root="7b00e758-e85b-4a5a-9a9c-5ebe194300d6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Susceptibility Testing</content>
                              </paragraph>
                              <paragraph>For specific information regarding susceptibility test interpretive criteria, and associated test methods and quality control standards recognized by FDA for daptomycin, please see: <linkHtml href="https://www.fda.gov/STIC">https://www.fda.gov/STIC</linkHtml>. </paragraph>
                           </text>
                           <effectiveTime value="20250228"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="899f18ca-322a-4f12-a1ff-c202971c9604"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20220818"/>
               <component>
                  <section ID="S13.1">
                     <id root="dae13846-7f38-427d-9108-c7a5d02f67f7"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Long-term carcinogenicity studies in animals have not been conducted to evaluate the carcinogenic potential of daptomycin for injection. However, neither mutagenic nor clastogenic potential was found in a battery of genotoxicity tests, including the Ames assay, a mammalian cell gene mutation assay, a test for chromosomal aberrations in Chinese hamster ovary cells, an <content styleCode="italics">in vivo</content> micronucleus assay, an <content styleCode="italics">in vitro</content> DNA repair assay, and an <content styleCode="italics">in vivo</content> sister chromatid exchange assay in Chinese hamsters.</paragraph>
                        <paragraph>Daptomycin did not affect the fertility or reproductive performance of male and female rats when administered intravenously at doses of 25, 75, or 150 mg/kg/day, which is approximately up to 9 times the estimated human exposure level based upon AUC<sub>s</sub> (or approximately up to 4 times the recommended human dose of 6 mg/kg based on body surface area comparison).</paragraph>
                     </text>
                     <effectiveTime value="20220818"/>
                  </section>
               </component>
               <component>
                  <section ID="S13.2">
                     <id root="2884154a-c6e2-4bb1-a95b-1bb38c2659b5"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2 Animal Toxicology and/or Pharmacology</title>
                     <effectiveTime value="20220818"/>
                     <component>
                        <section ID="ID_a9e3555b-7e6b-487c-8f37-f046f42e7fd0">
                           <id root="c1947a01-d6b2-4dac-8ae8-3d9bcca455e6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adult Animals</content>
                              </paragraph>
                              <paragraph>In animals, daptomycin administration has been associated with effects on skeletal muscle. However, there were no changes in cardiac or smooth muscle. Skeletal muscle effects were characterized by microscopic degenerative/regenerative changes and variable elevations in creatine phosphokinase (CPK). No fibrosis or rhabdomyolysis was evident in repeat-dose studies up to the highest doses tested in rats (150 mg/kg/day) and dogs (100 mg/kg/day). The degree of skeletal myopathy showed no increase when treatment was extended from 1 month to up to 6 months. Severity was dose-dependent. All muscle effects, including microscopic changes, were fully reversible within 30 days following the cessation of dosing.</paragraph>
                              <paragraph>In adult animals, effects on peripheral nerve (characterized by axonal degeneration and frequently accompanied by significant losses of patellar reflex, gag reflex, and pain perception) were observed at daptomycin doses higher than those associated with skeletal myopathy. Deficits in the dogs' patellar reflexes were seen within 2 weeks after the start of treatment at 40 mg/kg/day (9 times the human C<sub>max</sub> at the 6 mg/kg/day dose), with some clinical improvement noted within 2 weeks after the cessation of dosing. However, at 75 mg/kg/day for 1 month, 7 of 8 dogs failed to regain full patellar reflex responses within a 3-month recovery period. In a separate study in dogs receiving doses of 75 and 100 mg/kg/day for 2 weeks, minimal residual histological changes were noted at 6 months after the cessation of dosing. However, recovery of peripheral nerve function was evident.</paragraph>
                              <paragraph>Tissue distribution studies in rats showed that daptomycin is retained in the kidney but appears to penetrate the blood-brain barrier only minimally following single and multiple doses.</paragraph>
                           </text>
                           <effectiveTime value="20220818"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_6ef5a4b9-3297-4370-8ca4-939ed8c92509">
                           <id root="3fbdff00-fe17-4728-abbd-bab6568d2ac2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Juvenile Animals</content>
                              </paragraph>
                              <paragraph>Target organs of daptomycin-related effects in 7-week-old juvenile dogs were skeletal muscle and nerve, the same target organs as in adult dogs. In juvenile dogs, nerve effects were noted at lower daptomycin blood concentrations than in adult dogs following 28 days of dosing. In contrast to adult dogs, juvenile dogs also showed evidence of effects in nerves of the spinal cord as well as peripheral nerves after 28 days of dosing. No nerve effects were noted in juvenile dogs following 14 days of dosing at doses up to 75 mg/kg/day.</paragraph>
                              <paragraph>Administration of daptomycin to 7-week-old juvenile dogs for 28 days at doses of 50 mg/kg/day produced minimal degenerative effects on the peripheral nerve and spinal cord in several animals, with no corresponding clinical signs. A dose of 150 mg/kg/day for 28 days produced minimal degeneration in the peripheral nerve and spinal cord as well as minimal to mild degeneration of the skeletal muscle in a majority of animals, accompanied by slight to severe muscle weakness evident in most dogs. Following a 28-day recovery phase, microscopic examination revealed recovery of the skeletal muscle and the ulnar nerve effects, but nerve degeneration in the sciatic nerve and spinal cord was still observed in all 150 mg/kg/day dogs.</paragraph>
                              <paragraph>Following once-daily administration of daptomycin to juvenile dogs for 28 days, microscopic effects in nerve tissue were noted at a C<sub>max</sub> value of 417 mcg/mL, which is approximately 3-fold less than the C<sub>max</sub> value associated with nerve effects in adult dogs treated once daily with daptomycin for 28 days (1,308 mcg/mL).</paragraph>
                           </text>
                           <effectiveTime value="20220818"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_6fd5df50-6e6e-499b-bbef-471d648d6d8f">
                           <id root="692d3877-2c3f-4605-8e04-e149f106a675"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Neonatal Animals</content>
                              </paragraph>
                              <paragraph>Neonatal dogs (4 to 31 days old) were more sensitive to daptomycin-related adverse nervous system and/or muscular system effects than either juvenile or adult dogs. In neonatal dogs, adverse nervous system and/or muscular system effects were associated with a C<sub>max</sub> value approximately 3-fold less than the C<sub>max</sub> in juvenile dogs, and 9-fold less than the C<sub>max</sub> in adult dogs following 28 days of dosing. At a dose of 25 mg/kg/day with associated C<sub>max</sub> and AUC<sub>inf</sub> values of 147 mcg/mL and 717 mcg∙h/mL, respectively (1.6 and 1.0-fold the adult human C<sub>max</sub> and AUC, respectively, at the 6 mg/kg/day dose), mild clinical signs of twitching and one incidence of muscle rigidity were observed with no corresponding effect on body weight. These effects were found to be reversible within 28 days after treatment had stopped.</paragraph>
                              <paragraph>At higher dose levels of 50 and 75 mg/kg/day with associated C<sub>max</sub> and AUC<sub>inf</sub> values of ≥321 mcg/mL and ≥1,470 mcg∙h/mL, respectively, marked clinical signs of twitching, muscle rigidity in the limbs, and impaired use of limbs were observed. Resulting decreases in body weights and overall body condition at doses ≥50 mg/kg/day necessitated early discontinuation by postnatal day (PND) 19.</paragraph>
                              <paragraph>Histopathological assessment did not reveal any daptomycin-related changes in the peripheral and central nervous system tissue, as well as in the skeletal muscle or other tissues assessed, at any dose level.</paragraph>
                              <paragraph>No adverse effects were observed in the dogs that received daptomycin at 10 mg/kg/day, the NOAEL, with associated C<sub>max</sub> and AUC<sub>inf</sub> values of 62 mcg/mL and 247 mcg∙h/mL, respectively (or 0.6 and 0.4-fold the adult human C<sub>max</sub> and AUC, respectively at the 6 mg/kg dose).</paragraph>
                           </text>
                           <effectiveTime value="20220818"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="f127bbe6-b30d-4fba-9bce-43b86b55b09c"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20250228"/>
               <component>
                  <section ID="S14.1">
                     <id root="a4d4112f-37d2-4902-9f4b-dd9eda0da050"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1	Complicated Skin and Skin Structure Infections</title>
                     <effectiveTime value="20250228"/>
                     <component>
                        <section ID="ID_be55cff5-b221-4de8-9303-23561fdb381a">
                           <id root="f6ce2d58-3ce4-40fb-901d-e1304b29708e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adults with cSSSI</content>
                              </paragraph>
                              <paragraph>Adult patients with clinically documented complicated skin and skin structure infections (cSSSI) (Table 9) were enrolled in two randomized, multinational, multi-center, investigator-blinded trials comparing daptomycin for injection (4 mg/kg IV every 24h) with either vancomycin (1 g IV every 12h) or an anti-staphylococcal semi-synthetic penicillin (i.e., nafcillin, oxacillin, cloxacillin, or flucloxacillin; 4 to 12 g IV per day). Patients could switch to oral therapy after a minimum of 4 days of IV treatment if clinical improvement was demonstrated. Patients known to have bacteremia at baseline were excluded. Patients with creatinine clearance (CL<sub>CR</sub>) between 30 and 70 mL/min were to receive a lower dose of daptomycin for injection as specified in the protocol; however, the majority of patients in this subpopulation did not have the dose of daptomycin for injection adjusted.</paragraph>
                              <table ID="_Reftable9" width="85%">
                                 <caption>Table 9: Investigator's Primary Diagnosis in the cSSSI Trials in Adult Patients (Population: ITT)</caption>
                                 <col width="24%"/>
                                 <col width="25%"/>
                                 <col width="25%"/>
                                 <col width="25%"/>
                                 <thead>
                                    <tr>
                                       <th align="left" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                          <content styleCode="bold">Primary Diagnosis</content>
                                       </th>
                                       <th align="center" colspan="3" styleCode="Rrule Botrule Toprule " valign="middle">
                                          <content styleCode="bold">Adult Patients (Daptomycin for Injection/ Comparator</content>
                                          <footnote ID="_RefID0EN4AI">Comparator: vancomycin (1 g IV every 12h) or an anti-staphylococcal semi-synthetic penicillin (i.e., nafcillin, oxacillin, cloxacillin, or flucloxacillin; 4 to 12 g/day IV in divided doses).</footnote>
                                          <content styleCode="bold">)</content>
                                       </th>
                                    </tr>
                                    <tr>
                                       <th align="center" styleCode="Rrule Botrule " valign="middle">
                                          <content styleCode="bold">Study 9801</content>
                                          <br/>
                                          <content styleCode="bold">N=264/N=266</content>
                                       </th>
                                       <th align="center" styleCode="Rrule Botrule " valign="middle">
                                          <content styleCode="bold">Study 9901</content>
                                          <br/>
                                          <content styleCode="bold">N=270/N=292</content>
                                       </th>
                                       <th align="center" styleCode="Rrule Botrule " valign="middle">
                                          <content styleCode="bold">Pooled</content>
                                          <br/>
                                          <content styleCode="bold">N=534/N=558</content>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                          <paragraph>Wound Infection</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Toprule Botrule " valign="middle">
                                          <paragraph>99 (38%)/116 (44%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Toprule Botrule " valign="middle">
                                          <paragraph>102 (38%)/108 (37%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Toprule Botrule " valign="middle">
                                          <paragraph>201 (38%)/224 (40%)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="middle">
                                          <paragraph>Major Abscess</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="middle">
                                          <paragraph>55 (21%)/43 (16%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="middle">
                                          <paragraph>59 (22%)/65 (22%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="middle">
                                          <paragraph>114 (21%)/108 (19%)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="middle">
                                          <paragraph>Ulcer Infection</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="middle">
                                          <paragraph>71 (27%)/75 (28%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="middle">
                                          <paragraph>53 (20%)/68 (23%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="middle">
                                          <paragraph>124 (23%)/143 (26%)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Botrule Lrule " valign="middle">
                                          <paragraph>Other Infection<footnote ID="_RefID0ED6AI">The majority of cases were subsequently categorized as complicated cellulitis, major abscesses, or traumatic wound infections.</footnote>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="middle">
                                          <paragraph>39 (15%)/32 (12%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="middle">
                                          <paragraph>56 (21%)/51 (18%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="middle">
                                          <paragraph>95 (18%)/83 (15%)</paragraph>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>One trial was conducted primarily in the United States and South Africa (study 9801), and the second was conducted at non-US sites only (study 9901). The two trials were similar in design but differed in patient characteristics, including history of diabetes and peripheral vascular disease. There were a total of 534 adult patients treated with daptomycin for injection and 558 treated with comparator in the two trials. The majority (89.7%) of patients received IV medication exclusively.</paragraph>
                              <paragraph>The efficacy endpoints in both trials were the clinical success rates in the intent-to-treat (ITT) population and in the clinically evaluable (CE) population. In study 9801, clinical success rates in the ITT population were 62.5% (165/264) in patients treated with daptomycin for injection and 60.9% (162/266) in patients treated with comparator drugs. Clinical success rates in the CE population were 76.0% (158/208) in patients treated with daptomycin for injection and 76.7% (158/206) in patients treated with comparator drugs. In study 9901, clinical success rates in the ITT population were 80.4% (217/270) in patients treated with daptomycin for injection and 80.5% (235/292) in patients treated with comparator drugs. Clinical success rates in the CE population were 89.9% (214/238) in patients treated with daptomycin for injection and 90.4% (226/250) in patients treated with comparator drugs.</paragraph>
                              <paragraph>The success rates by pathogen for microbiologically evaluable patients are presented in Table 10.</paragraph>
                              <table ID="_Reftable10" width="85%">
                                 <caption>Table 10: Clinical Success Rates by Infecting Pathogen in the cSSSI Trials in Adult Patients (Population: Microbiologically Evaluable)</caption>
                                 <col width="33%"/>
                                 <col width="33%"/>
                                 <col width="32%"/>
                                 <thead>
                                    <tr>
                                       <th align="left" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                          <content styleCode="bold">Pathogen</content>
                                       </th>
                                       <th align="center" colspan="2" styleCode="Rrule Botrule Toprule " valign="middle">
                                          <content styleCode="bold">Success Rate n/N (%)</content>
                                       </th>
                                    </tr>
                                    <tr>
                                       <th align="center" styleCode="Rrule Botrule " valign="top">
                                          <content styleCode="bold">Daptomycin for Injection</content>
                                       </th>
                                       <th align="center" styleCode="Rrule Botrule " valign="top">
                                          <content styleCode="bold">Comparator</content>
                                          <footnote ID="_RefID0EOABI">Comparator: vancomycin (1 g IV every 12h) or an anti-staphylococcal semi-synthetic penicillin (i.e., nafcillin, oxacillin, cloxacillin, or flucloxacillin; 4 to 12 g/day IV in divided doses).</footnote>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                          <paragraph>Methicillin-susceptible <content styleCode="italics">Staphylococcus aureus</content> (MSSA) <footnote ID="_Reffoot10b">As determined by the central laboratory.</footnote>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Toprule Botrule " valign="middle">
                                          <paragraph>170/198 (86%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Toprule Botrule " valign="middle">
                                          <paragraph>180/207 (87%)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="middle">
                                          <paragraph>Methicillin-resistant <content styleCode="italics">Staphylococcus aureus</content> (MRSA) <footnoteRef IDREF="_Reffoot10b"/>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="middle">
                                          <paragraph>21/28 (75%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="middle">
                                          <paragraph>25/36 (69%)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="middle">
                                          <paragraph>
                                             <content styleCode="italics">Streptococcus pyogenes</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="middle">
                                          <paragraph>79/84 (94%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="middle">
                                          <paragraph>80/88 (91%)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="middle">
                                          <paragraph>
                                             <content styleCode="italics">Streptococcus agalactiae</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="middle">
                                          <paragraph>23/27 (85%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="middle">
                                          <paragraph>22/29 (76%)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="middle">
                                          <paragraph>
                                             <content styleCode="italics">Streptococcus dysgalactiae</content> subsp. <content styleCode="italics">equisimilis</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="middle">
                                          <paragraph>8/8 (100%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="middle">
                                          <paragraph>9/11 (82%)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Botrule Lrule " valign="middle">
                                          <paragraph>
                                             <content styleCode="italics">Enterococcus faecalis</content> (vancomycin-susceptible only)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="middle">
                                          <paragraph>27/37 (73%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="middle">
                                          <paragraph>40/53 (76%)</paragraph>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250228"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S14.2">
                     <id root="1e4ed9f8-1421-439d-8173-bc8ccaf023ee"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2	<content styleCode="italics">S. aureus</content> Bacteremia/Endocarditis</title>
                     <effectiveTime value="20250228"/>
                     <component>
                        <section ID="ID_01deaa6a-2fcb-4cbe-b1d7-ee8e04ab2c0d">
                           <id root="f2568187-ca98-4436-96a7-4b4dcfd096fa"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adults with <content styleCode="italics">S. aureus</content> Bacteremia/Endocarditis</content>
                              </paragraph>
                              <paragraph>The efficacy of daptomycin for injection in the treatment of adult patients with <content styleCode="italics">S. aureus</content> bacteremia was demonstrated in a randomized, controlled, multinational, multi-center, open-label trial. In this trial, adult patients with at least one positive blood culture for <content styleCode="italics">S. aureus</content> obtained within 2 calendar days prior to the first dose of study drug and irrespective of source were enrolled and randomized to either daptomycin for injection (6 mg/kg IV every 24h) or standard of care [an anti-staphylococcal semi-synthetic penicillin 2 g IV every 4h (nafcillin, oxacillin, cloxacillin, or flucloxacillin) or vancomycin 1 g IV every 12h, each with initial gentamicin 1 mg/kg IV every 8 hours for first 4 days]. Of the patients in the comparator group, 93% received initial gentamicin for a median of 4 days, compared with 1 patient (&lt;1%) in the daptomycin for injection group. Patients with prosthetic heart valves, intravascular foreign material that was not planned for removal within 4 days after the first dose of study medication, severe neutropenia, known osteomyelitis, polymicrobial bloodstream infections, creatinine clearance &lt;30 mL/min, and pneumonia were excluded.</paragraph>
                              <paragraph>Upon entry, patients were classified for likelihood of endocarditis using the modified Duke criteria (Possible, Definite, or Not Endocarditis). Echocardiography, including a transesophageal echocardiogram (TEE), was performed within 5 days following study enrollment. The choice of comparator agent was based on the oxacillin susceptibility of the <content styleCode="italics">S. aureus</content> isolate. The duration of study treatment was based on the investigator's clinical diagnosis. Final diagnoses and outcome assessments at Test of Cure (6 weeks after the last treatment dose) were made by a treatment-blinded Adjudication Committee, using protocol-specified clinical definitions and a composite primary efficacy endpoint (clinical and microbiological success) at the Test of Cure visit.</paragraph>
                              <paragraph>A total of 246 patients ≥18 years of age (124 daptomycin for injection, 122 comparator) with <content styleCode="italics">S. aureus</content> bacteremia were randomized from 48 centers in the US and Europe. In the ITT population, 120 patients received daptomycin for injection and 115 received comparator (62 received an anti-staphylococcal semi synthetic penicillin and 53 received vancomycin). Thirty-five patients treated with an anti-staphylococcal semi-synthetic penicillin received vancomycin initially for 1 to 3 days, pending final susceptibility results for the <content styleCode="italics">S. aureus</content> isolates. The median age among the 235 patients in the ITT population was 53 years (range: 21 to 91 years); 30/120 (25%) in the daptomycin for injection group and 37/115 (32%) in the comparator group were ≥65 years of age. Of the 235 ITT patients, there were 141 (60%) males and 156 (66%) Caucasians across the two treatment groups. In addition, 176 (75%) of the ITT population had systemic inflammatory response syndrome (SIRS) at baseline and 85 (36%) had surgical procedures within 30 days prior to onset of the <content styleCode="italics">S. aureus</content> bacteremia. Eighty-nine patients (38%) had bacteremia caused by methicillin-resistant <content styleCode="italics">S. aureus</content> (MRSA). Entry diagnosis was based on the modified Duke criteria and comprised 37 (16%) Definite, 144 (61%) Possible, and 54 (23%) Not Endocarditis. Of the 37 patients with an entry diagnosis of Definite Endocarditis, all (100%) had a final diagnosis of infective endocarditis, and of the 144 patients with an entry diagnosis of Possible Endocarditis, 15 (10%) had a final diagnosis of infective endocarditis as assessed by the Adjudication Committee. Of the 54 patients with an entry diagnosis of Not Endocarditis, 1 (2%) had a final diagnosis of infective endocarditis as assessed by the Adjudication Committee.</paragraph>
                              <paragraph>In the ITT population, there were 182 patients with bacteremia and 53 patients with infective endocarditis as assessed by the Adjudication Committee, including 35 with right-sided endocarditis and 18 with left-sided endocarditis. The 182 patients with bacteremia comprised 121 with complicated <content styleCode="italics">S. aureus</content> bacteremia and 61 with uncomplicated <content styleCode="italics">S. aureus</content> bacteremia.</paragraph>
                              <paragraph>Complicated bacteremia was defined as <content styleCode="italics">S. aureus</content> isolated from blood cultures obtained on at least 2 different calendar days, and/or metastatic foci of infection (deep tissue involvement), and classification of the patient as not having endocarditis according to the modified Duke criteria. Uncomplicated bacteremia was defined as <content styleCode="italics">S. aureus</content> isolated from blood culture(s) obtained on a single calendar day, no metastatic foci of infection, no infection of prosthetic material, and classification of the patient as not having endocarditis according to the modified Duke criteria. The definition of right-sided infective endocarditis (RIE) used in the clinical trial was Definite or Possible Endocarditis according to the modified Duke criteria and no echocardiographic evidence of predisposing pathology or active involvement of either the mitral or aortic valve. Complicated RIE comprised patients who were not intravenous drug users, had a positive blood culture for MRSA, serum creatinine ≥2.5 mg/dL, or evidence of extrapulmonary sites of infection. Patients who were intravenous drug users, had a positive blood culture for methicillin-susceptible <content styleCode="italics">S. aureus</content> (MSSA), had serum creatinine &lt;2.5 mg/dL, and were without evidence of extrapulmonary sites of infection were considered to have uncomplicated RIE.</paragraph>
                              <paragraph>The coprimary efficacy endpoints in the trial were the Adjudication Committee success rates at the Test of Cure visit (6 weeks after the last treatment dose) in the ITT and Per Protocol (PP) populations. The overall Adjudication Committee success rates in the ITT population were 44.2% (53/120) in patients treated with daptomycin for injection and 41.7% (48/115) in patients treated with comparator (difference = 2.4% [95% CI−10.2, 15.1]). The success rates in the PP population were 54.4% (43/79) in patients treated with daptomycin for injection and 53.3% (32/60) in patients treated with comparator (difference = 1.1% [95% CI−15.6, 17.8]).</paragraph>
                              <paragraph>Adjudication Committee success rates are shown in Table 11.</paragraph>
                              <table ID="_Reftable11" width="85%">
                                 <caption>Table 11: Adjudication Committee Success Rates at Test of Cure in the S. aureus Bacteremia/Endocarditis Trial in Adult Patients (Population: ITT)</caption>
                                 <col width="25%"/>
                                 <col width="25%"/>
                                 <col width="24%"/>
                                 <col width="24%"/>
                                 <thead>
                                    <tr>
                                       <th align="left" rowspan="2" styleCode="Rrule Lrule Toprule " valign="middle">
                                          <content styleCode="bold">Population</content>
                                       </th>
                                       <th align="center" colspan="2" styleCode="Rrule Botrule Toprule " valign="top">
                                          <content styleCode="bold">Success Rate n/N (%)</content>
                                       </th>
                                       <th align="center" rowspan="2" styleCode="Rrule Toprule " valign="top">
                                          <content styleCode="bold">Difference:</content>
                                          <br/>
                                          <content styleCode="bold">Daptomycin for Injection-Comparator (Confidence Interval)</content>
                                       </th>
                                    </tr>
                                    <tr>
                                       <th align="center" styleCode="Rrule Botrule " valign="top">
                                          <content styleCode="bold">Daptomycin for Injection 6 mg/kg</content>
                                       </th>
                                       <th align="center" styleCode="Rrule Botrule " valign="top">
                                          <content styleCode="bold">Comparator</content>
                                          <footnote ID="_Reffoot11a">Comparator: vancomycin (1 g IV every 12h) or an anti-staphylococcal semi-synthetic penicillin (i.e., nafcillin, oxacillin, cloxacillin, or flucloxacillin; 2 g IV every 4h), each with initial low-dose gentamicin.</footnote>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>Overall</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                          <paragraph>53/120 (44%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                          <paragraph>48/115 (42%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                          <paragraph>2.4% (-10.2, 15.1) <footnote ID="_Reffoot11b">95% Confidence Interval.</footnote>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Baseline Pathogen</paragraph>
                                       </td>
                                       <td styleCode="Rrule Botrule " valign="top"/>
                                       <td styleCode="Rrule Botrule " valign="top"/>
                                       <td styleCode="Rrule Botrule " valign="top"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Methicillin-susceptible <content styleCode="italics">S. aureus</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>33/74 (45%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>34/70 (49%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>-4.0% (-22.6, 14.6) <footnote ID="_Reffoot11c">97.5% Confidence Interval (adjusted for multiplicity).</footnote>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Methicillin-resistant <content styleCode="italics">S. aureus</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>20/45 (44%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>14/44 (32%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>12.6% (-10.2, 35.5) <footnoteRef IDREF="_Reffoot11c"/>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Entry Diagnosis<footnote ID="_Reffoot11d">According to the modified Duke criteria<sup>5</sup>.</footnote>
                                          </paragraph>
                                       </td>
                                       <td styleCode="Rrule Botrule " valign="top"/>
                                       <td styleCode="Rrule Botrule " valign="top"/>
                                       <td styleCode="Rrule Botrule " valign="top"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Definite or Possible Infective Endocarditis</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>41/90 (46%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>37/91 (41%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>4.9% (-11.6, 21.4) <footnoteRef IDREF="_Reffoot11c"/>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Not Infective Endocarditis</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>12/30 (40%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>11/24 (46%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>-5.8% (-36.2, 24.5) <footnoteRef IDREF="_Reffoot11c"/>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Final Diagnosis</paragraph>
                                       </td>
                                       <td styleCode="Rrule Botrule " valign="top"/>
                                       <td styleCode="Rrule Botrule " valign="top"/>
                                       <td styleCode="Rrule Botrule " valign="top"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Uncomplicated Bacteremia</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>18/32 (56%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>16/29 (55%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>1.1% (-31.7, 33.9) <footnote ID="_Reffoot11e">99% Confidence Interval (adjusted for multiplicity).</footnote>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Complicated Bacteremia</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>26/60 (43%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>23/61 (38%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>5.6% (-17.3, 28.6) <footnoteRef IDREF="_Reffoot11e"/>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Right-Sided Infective Endocarditis</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>8/19 (42%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>7/16 (44%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>-1.6% (-44.9, 41.6) <footnoteRef IDREF="_Reffoot11e"/>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Uncomplicated Right-Sided Infective Endocarditis</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>3/6 (50%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>1/4 (25%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>25.0% (-51.6, 100.0) <footnoteRef IDREF="_Reffoot11e"/>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Complicated Right-Sided Infective Endocarditis</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>5/13 (39%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>6/12 (50%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>-11.5% (-62.4, 39.4) <footnoteRef IDREF="_Reffoot11e"/>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Botrule Lrule " valign="top">
                                          <paragraph>Left-Sided Infective Endocarditis</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>1/9 (11%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>2/9 (22%)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>-11.1% (-55.9, 33.6) <footnoteRef IDREF="_Reffoot11e"/>
                                          </paragraph>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Eighteen (18/120) patients in the daptomycin for injection arm and 19/116 patients in the comparator arm died during the trial. These comprise 3/28 daptomycin for injection-treated patients and 8/26 comparator-treated patients with endocarditis, as well as 15/92 daptomycin for injection-treated patients and 11/90 comparator-treated patients with bacteremia. Among patients with persisting or relapsing <content styleCode="italics">S. aureus</content> infections, 8/19 daptomycin for injection-treated patients and 7/11 comparator-treated patients died.</paragraph>
                              <paragraph>Overall, there was no difference in time to clearance of <content styleCode="italics">S. aureus</content> bacteremia between daptomycin for injection and comparator. The median time to clearance in patients with MSSA was 4 days and in patients with MRSA was 8 days.</paragraph>
                              <paragraph>Failure of treatment due to persisting or relapsing <content styleCode="italics">S. aureus</content> infections was assessed by the Adjudication Committee in 19/120 (16%) daptomycin for injection-treated patients (12 with MRSA and 7 with MSSA) and 11/115 (10%) comparator-treated patients (9 with MRSA treated with vancomycin and 2 with MSSA treated with an anti-staphylococcal semi-synthetic penicillin). Among all failures, isolates from 6 daptomycin for injection-treated patients and 1 vancomycin-treated patient developed increasing MICs (reduced susceptibility) by central laboratory testing during or following therapy. Most patients who failed due to persisting or relapsing <content styleCode="italics">S. aureus</content> infection had deep-seated infection and did not receive necessary surgical intervention <content styleCode="italics">[see <linkHtml href="#S5.9">Warnings and Precautions (5.9)</linkHtml>].</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250228"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S15">
               <id root="af8fa59b-f032-4f7b-b373-d82998eec34b"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>15 REFERENCES</title>
               <text>
                  <list listType="ordered">
                     <item>
                        <caption>1.</caption>Liu SL, Howard LC, Van Lier RBL, Markham JK: Teratology studies with daptomycin administered intravenously (iv) to rats and rabbits. Teratology 37(5):475, 1988.</item>
                     <item>
                        <caption>2.</caption>Stroup JS, Wagner J, Badzinski T: Use of daptomycin in a pregnant patient with <content styleCode="italics">Staphylococcus aureus</content> endocarditis. Ann Pharmacother 44(4):746–749, 2010.</item>
                     <item>
                        <caption>3.</caption>Buitrago MI, Crompton JA, Bertolami S, North DS, Nathan RA. Extremely low excretion of daptomycin into breast milk of a nursing mother with methicillin-resistant <content styleCode="italics">Staphylococcus aureus</content> pelvic inflammatory disease. Pharmacotherapy 2009;29(3):347–351.</item>
                     <item>
                        <caption>4.</caption>Klibanov OM, Vickery S, Nortey C: Successful treatment of infective panniculitis with daptomycin in a pregnant, morbidly obese patient. Ann Pharmacother 48(5):652–655, 2014.</item>
                     <item>
                        <caption>5.</caption>Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, Ryan T, Bashore T, Corey GR. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000;30:633–638.</item>
                  </list>
               </text>
               <effectiveTime value="20220818"/>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="9eacb929-0618-4fe4-810c-8d61e80fab2f"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Daptomycin for Injection is supplied as a sterile pale yellow to light brown lyophilized cake in a single-dose vial containing either 350 mg or 500 mg of daptomycin: </paragraph>
                  <table width="85%">
                     <col width="49%"/>
                     <col width="49%"/>
                     <thead>
                        <tr>
                           <th align="left" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                              <content styleCode="bold">Unit of Sale</content>
                           </th>
                           <th align="left" styleCode="Rrule Botrule Toprule " valign="middle">
                              <content styleCode="bold">Strength</content>
                           </th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">NDC 0409-0120-01</content>
                                 <br/>Carton containing 1 single-dose vial</paragraph>
                           </td>
                           <td styleCode="Rrule Toprule Botrule " valign="middle">
                              <paragraph>350 mg/vial</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">NDC 0409-0122-01</content>
                                 <br/>Carton containing 1 single-dose vial</paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="middle">
                              <paragraph>500 mg/vial</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20220818"/>
               <component>
                  <section ID="ID_81bf2c06-400e-4682-a583-9ab830650dcc">
                     <id root="e520f180-c903-49e0-a69b-e4fe468a8ace"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>Store original packages at 2°C to 25°C (36°F to 77°F); do not freeze. Brief exposure to 30°C (86°F) permitted [see USP Controlled Room Temperature] <content styleCode="italics">[see <linkHtml href="#S2.5">Dosage and Administration (2.5)</linkHtml>]</content>. Storage conditions for the reconstituted and diluted solutions are described in another section of the prescribing information <content styleCode="italics">[see <linkHtml href="#S2.5">Dosage and Administration (2.5)</linkHtml>]</content>.</paragraph>
                        <paragraph>The vial stopper is not made with natural rubber latex.</paragraph>
                     </text>
                     <effectiveTime value="20220818"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="ca0878ba-c291-4d5a-b2e4-d1d7fe6cb9db"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <effectiveTime value="20220818"/>
               <component>
                  <section ID="ID_03632f9f-6962-44a9-bba0-94750d351635">
                     <id root="3348012f-3e12-4a24-bd49-b836dcd749de"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Allergic Reactions</content>
                        </paragraph>
                        <paragraph>Advise patients that allergic reactions, including serious skin, kidney, lung, or other organ reactions, could occur and that these serious reactions require immediate treatment. Patients should report any previous allergic reactions to daptomycin <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1</linkHtml>, <linkHtml href="#S5.4">5.4</linkHtml>, <linkHtml href="#S5.5">5.5)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220818"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_568f745c-4bf8-4494-a6f3-4e5c027ec8f9">
                     <id root="769d171d-4045-42ed-801c-96e82cd1e76c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Muscle Pain or Weakness (Myopathy and Rhabdomyolysis, Peripheral Neuropathy)</content>
                        </paragraph>
                        <paragraph>Advise patients to report muscle pain or weakness, especially in the forearms and lower legs, as well as tingling or numbness <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2</linkHtml>, <linkHtml href="#S5.6">5.6)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220818"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_6c95b9f9-fd59-4dae-b321-8e1aebda8eff">
                     <id root="45d7796f-71a1-4b6f-8480-2191eaec9ba8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Cough, Breathlessness or Fever (Eosinophilic Pneumonia)</content>
                        </paragraph>
                        <paragraph>Advise patients to report any symptoms of cough, breathlessness, or fever <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220818"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_7c1dfd2b-c9ba-4cae-aabf-40dbbe0a2d99">
                     <id root="cce0176f-61ff-4179-8fb9-5fb44214f16e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">
                              <content styleCode="italics">C. difficile</content>-Associated Diarrhea (CDAD)</content>
                        </paragraph>
                        <paragraph>Advise patients that diarrhea is a common problem caused by antibacterials, including Daptomycin for Injection that usually ends when the antibacterial is discontinued. Sometimes after starting treatment with antibacterials, including Daptomycin for Injection, patients can develop watery and bloody stools (with or without stomach cramps and fever), even as late as 2 or more months after having received the last dose of the antibacterial. If this occurs, patients should contact their physician as soon as possible <content styleCode="italics">[see <linkHtml href="#S5.8">Warnings and Precautions (5.8)</linkHtml>]</content>,</paragraph>
                     </text>
                     <effectiveTime value="20220818"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_9cff16da-3cbc-474a-aaeb-dee2fb300e91">
                     <id root="d7b4e3d8-64f6-4c91-8a44-14526d9dace8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Antibacterial Resistance</content>
                        </paragraph>
                        <paragraph>Patients should be counseled that antibacterial drugs, including Daptomycin for Injection, should be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Daptomycin for Injection is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be administered exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Daptomycin for Injection or other antibacterial drugs in the future.</paragraph>
                     </text>
                     <effectiveTime value="20220818"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_9368375e-edd7-4467-823a-3cf033f13372">
               <id root="f176c98f-b630-4d5f-9c1c-d0b659d6cbb7"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <renderMultiMedia ID="id2831" referencedObject="MM2"/>
                  <paragraph>Distributed by Hospira, Inc., Lake Forest, IL 60045 USA</paragraph>
                  <paragraph>LAB-1007-4.0</paragraph>
               </text>
               <effectiveTime value="20250228"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>Logo</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="daptomycin-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_07cbf52d-696c-4a89-b2a5-aa9663f8a92e">
               <id root="3c575ed7-7f79-40d8-92b8-4bc8500c09f4"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 500 mg Vial Label</title>
               <text>
                  <paragraph>NDC 0409-0122-01</paragraph>
                  <paragraph>Daptomycin<br/>for Injection</paragraph>
                  <paragraph>500 mg per vial</paragraph>
                  <paragraph>Must be reconstituted<br/>For Intravenous Use</paragraph>
                  <paragraph>Single dose vial - Discard Unused Portion</paragraph>
                  <renderMultiMedia ID="id2855" referencedObject="MM3"/>
               </text>
               <effectiveTime value="20220818"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>PRINCIPAL DISPLAY PANEL - 500 mg Vial Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="daptomycin-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_074e949c-fee7-4dd5-a1cf-fc6612b16456">
               <id root="4108ce24-8f3f-4a32-a0ee-7295b14e00ad"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 500 mg Vial Carton</title>
               <text>
                  <paragraph>NDC 0409-0122-01<br/>Rx only</paragraph>
                  <paragraph>Daptomycin<br/>for Injection</paragraph>
                  <paragraph>500 mg per vial</paragraph>
                  <paragraph>For Intravenous Use</paragraph>
                  <paragraph>Use 0.9% Sodium Chloride <br/>Injection, USP for<br/>reconstitution only.</paragraph>
                  <paragraph>Single-dose vial - <br/>Discard unused portion</paragraph>
                  <paragraph>Hospira</paragraph>
                  <renderMultiMedia ID="id2881" referencedObject="MM4"/>
               </text>
               <effectiveTime value="20220818"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>PRINCIPAL DISPLAY PANEL - 500 mg Vial Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="daptomycin-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_ea134462-2d43-49f0-b846-adf5c4924b6e">
               <id root="6ae53e87-e56e-426b-8639-fbdedb858cb3"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 350 mg Vial Label</title>
               <text>
                  <paragraph>NDC 0409-0120-01</paragraph>
                  <paragraph>Daptomycin<br/>for Injection</paragraph>
                  <paragraph>350 mg per vial</paragraph>
                  <paragraph>Must be reconstituted<br/>For Intravenous Use</paragraph>
                  <paragraph>Single dose vial - Discard Unused Portion</paragraph>
                  <renderMultiMedia ID="id2902" referencedObject="MM5"/>
               </text>
               <effectiveTime value="20220818"/>
               <component>
                  <observationMedia ID="MM5">
                     <text>PRINCIPAL DISPLAY PANEL - 350 mg Vial Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="daptomycin-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_ab31861c-4893-4d0a-93cf-60e2462387c2">
               <id root="e9c0d6e5-2c66-4d18-9e93-511cc41906b4"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 350 mg Vial Carton</title>
               <text>
                  <paragraph>NDC 0409-0120-01<br/>Rx only</paragraph>
                  <paragraph>Daptomycin<br/>for Injection</paragraph>
                  <paragraph>350 mg per vial</paragraph>
                  <paragraph>For Intravenous Use</paragraph>
                  <paragraph>Use 0.9% Sodium Chloride <br/>Injection, USP for<br/>reconstitution only.</paragraph>
                  <paragraph>Single-dose vial - <br/>Discard unused portion</paragraph>
                  <paragraph>Hospira</paragraph>
                  <renderMultiMedia ID="id2928" referencedObject="MM6"/>
               </text>
               <effectiveTime value="20220818"/>
               <component>
                  <observationMedia ID="MM6">
                     <text>PRINCIPAL DISPLAY PANEL - 350 mg Vial Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="daptomycin-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>